```
      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,155,399
       03dec09 13:49:31 User208760 Session D3131.2
            $0.00    0.117 DialUnits File410
     $0.00  Estimated cost File410
     $0.02  TELNET
     $0.02  Estimated cost this search
     $0.57  Estimated total session cost   0.271 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R) 1926-2009/Nov W5
         (c) 2009 The Thomson Corporation
  File  73:EMBASE 1974-2009/Dec 03
         (c) 2009 Elsevier B.V.
*File  73: UD20091118 contains data for November 16-18.
  File 155:MEDLINE(R) 1950-2009/Dec 01
         (c) format only 2009 Dialog
*File 155: Please see HELP NEWS 154 for information on updating
in Medline the month of November.
  File 399:CA SEARCH(R) 1967-2009/UD=15123
         (c) 2009 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

      Set  Items  Description
      ---  -----  -----------
? s (sgn(w)40 or cd40)(10n)(antibod?) and (rituxan or rituximab or
cd20)(10n)(antibod?)
            754  SGN
        1682881  40
            136  SGN(W)40
          39562  CD40
        2478061  ANTIBOD?
           6509  (SGN(W)40 OR CD40)(10N)ANTIBOD?
           2195  RITUXAN
          28350  RITUXIMAB
          25470  CD20
        2478061  ANTIBOD?
          15402  ((RITUXAN OR RITUXIMAB) OR CD20)(10N)ANTIBOD?
     S1     348  (SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR
                 RITUXIMAB OR CD20)(10N)(ANTIBOD?)
? and (cancer? or tumor? or tumour? or malign? or neoplas? or lymphoma? or leukemi?)
>>>Unrecognizable Command
? s s1 and (cancer? or tumor? or tumour? or malign? or neoplas? or lymphoma? or
leukemi?)
Processing
            348  S1
        3343764  CANCER?
        3468507  TUMOR?
         408756  TUMOUR?
         896805  MALIGN?
        3418542  NEOPLAS?
         431342  LYMPHOMA?
         749701  LEUKEMI?
     S2     244  S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR
                 NEOPLAS? OR LYMPHOMA? OR LEUKEMI?)
```

```
? rd s2
      S3     216  RD S2  (unique items)
? s s3 and py<2001
Processing
Processing
             216  S3
        52875556  PY<2001
      S4      13  S3 AND PY<2001
? t s4/3/all

 4/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

13701505   BIOSIS NO.: 199799335565
Increased inhibition of proliferation of human B cell lymphomas
  following ligation of CD40, and either CD19, CD20, CD95 or surface
  immunoglobulin
AUTHOR: Benoit Nicole E; Wade William F (Reprint)
AUTHOR ADDRESS: Dep. Microbiol., Dartmouth Med. Sch., Lebanon, NH 03756,
  USA**USA
JOURNAL: Immunopharmacology  35 (2): p129-139 1996 1996
ISSN: 0162-3109
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English


 4/3/2     (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

13374972   BIOSIS NO.: 199699009032
Differential in vitro and in vivo antitumor effects mediated by anti-
  CD40 and anti-CD20 monoclonal antibodies against human
  B-cell lymphomas
AUTHOR: Funakoshi Satoshi; Longo Dan L; Murphy William J (Reprint)
AUTHOR ADDRESS: Biological Carcinogenesis and Development Program, SAIC
  Frederick, Build. 567, Room 141, Frederick, MD 21702-1201, USA**USA
JOURNAL: Journal of Immunotherapy with Emphasis on Tumor Immunology  19 (2
): p93-101 1996 1996
ISSN: 1067-5582
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English


 4/3/3     (Item 3 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

13000597   BIOSIS NO.: 199598468430
Antibodies to CD40 prevent Epstein-Barr virus-mediated human
  B-cell lymphomagenesis in severe combined immune deficient mice
  given human peripheral blood lymphocytes
AUTHOR: Murphy William J (Reprint); Funakoshi Satoshi; Beckwith Margaret;
  Rushing Susan E; Conley Denise K; Armitage Richard J; Fanslow William C;
  Rager Helen C; Taub Dennis D; Ruscetti Francis W; Longo Dan L
AUTHOR ADDRESS: Biol. Carcinogenesis and Dev. Program, Program Resources
  Inc./DynCorp, NCI-FCRDC, Build. 567, Room 141, Frederick, MD 21702-1201,
  USA**USA
```

JOURNAL: Blood 86 (5): p1946-1953 1995 1995
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10749007 BIOSIS NO.: 199191131898
DETECTION OF ACTIVATION ANTIGENS ON CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
AUTHOR: PALOCZI K (Reprint); POCSIK E; MIHALIK R; BENCZUR M; DEMETER J; SOLTI V; PETRANYI G; HOLLAN S R
AUTHOR ADDRESS: NATL INST HAEMATOLOGY BLOOD TRANSFUSION, BUDAPEST, PO BOX 44, H-1502, HUNGARY**HUNGARY
JOURNAL: Leukemia and Lymphoma 3 (1): p31-36 1990
ISSN: 1042-8194
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

4/3/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

0078467424 EMBASE No: 2001073341
Overview of idiopathic thrombocytopenic purpura: New approach to refractory patients
Bussel J.B.
Weill Med. College of Cornell Univ., Department of Pediatrics, Div. of Pediatric Hematol./Oncology, 525 E 68th St, New York, NY 10021, United States
CORRESP. AUTHOR/AFFIL: Bussel J.B.: Weill Med. College of Cornell Univ., Department of Pediatrics, Div. of Pediatric Hematol./Oncology, 525 E 68th St, New York, NY 10021, United States

Seminars in Oncology (Semin. Oncol.) (United States) December 1, 2000, 27/6 SUPPL. 12 (91-98)
CODEN: SOLGA ISSN: 0093-7754
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 25

4/3/6 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

0076676499 EMBASE No: 1996352908
Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and iehter CD19, CD20, CD95 or surface immunoglobulin
Benoit N.E.; Wade W.F.
Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States
AUTHOR EMAIL: william.wade@dartmouth.edu
CORRESP. AUTHOR/AFFIL: Wade W.F.: Department of Microbiology, Dartmouth

Medical School, Lebanon, NH 03756, United States

Immunopharmacology (IMMUNOPHARMACOLOGY) (Netherlands) November 1, 1996
, 35/2 (129-139)
CODEN: IMMUD ISSN: 0162-3109
PUBLISHER ITEM IDENTIFIER: S0162310996001385
DOI: 10.1016/S0162-3109(96)00138-5
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 33

4/3/7 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2009 Dialog. All rts. reserv.

10283541 PMID: 1373168
IL-4 induces conformational change of CD20 antigen via a protein kinase
C-independent pathway. Antagonistic effect of anti- ***CD40*** monoclonal
antibody .
Dancescu M; Wu C; Rubio M; Delespesse G; Sarfati M
Notre-Dame Hospital, Research Center, University of Montreal, Quebec,
Canada.
Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) Apr 15
1992, 148 (8) p2411-6, ISSN 0022-1767--Print Journal Code:
2985117R
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

4/3/8 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

130218273 CA: 130(17)218273r PATENT
Phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for
controlling cellular proliferation
INVENTOR(AUTHOR): Schieven, Gary L.
LOCATION: USA
ASSIGNEE: Bristol-Myers Squibb Company
PATENT: United States ; US 5877210 A DATE: 19990302
APPLICATION: US 465813 (19950605) *US 189330 (19940131)
PAGES: 73 pp., Cont.-in-part of U.S. Ser. No. 189,330. CODEN: USXXAM
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 514492000; A01N-055/02A; A61K-039/395B; C07F-053/00B

4/3/9 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

128166354 CA: 128(14)166354e PATENT
Improved method of treating immune cell mediated systemic diseases
INVENTOR(AUTHOR): Davis, Charles Baldwin; Bugelski, Peter John;
MacDonald, Brian Richard
LOCATION: USA
ASSIGNEE: Smithkline Beecham Corpration; Davis, Charles Baldwin;

Bugelski, Peter John; MacDonald, Brian Richard
PATENT: PCT International ; WO 9804281 A1 DATE: 19980205
APPLICATION: WO 97US12600 (19970725) *US 22472 (19960726)
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/00A; A61K-039/395B; C07K-014/00B; C07K-014/705B;
C07K-016/00B
DESIGNATED COUNTRIES: JP; US DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES
; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

4/3/10 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126250224 CA: 126(19)250224d PATENT
Immunotherapeutic agents containing antibodies which specifically
recognize a patient's class II antigens
INVENTOR(AUTHOR): Lindhofer, Horst; Thierfelder, Stefan
LOCATION: Germany,
ASSIGNEE: GSF - Forschungszentrum fuer Umwelt und Gesundheit Gmbh
PATENT: Germany Offen. ; DE 19531346 A1 DATE: 19970227
APPLICATION: DE 19531346 (19950825)
PAGES: 16 pp. CODEN: GWXXBX LANGUAGE: German
PATENT CLASSIFICATIONS:
CLASS: C07K-016/00A; A61K-039/395B; A61K-051/10B

4/3/11 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126250223 CA: 126(19)250223c PATENT
Antibodies with two or more specificities for the selective elimination
of tumor cells in vivo
INVENTOR(AUTHOR): Lindhofer, Horst; Thierfelder, Stefan
LOCATION: Germany,
ASSIGNEE: GSF - Forschungszentrum fuer Umwelt und Gesundheit Gmbh
PATENT: Germany Offen. ; DE 19531348 A1 DATE: 19970227
APPLICATION: DE 19531348 (19950825)
PAGES: 17 pp. CODEN: GWXXBX LANGUAGE: German
PATENT CLASSIFICATIONS:
CLASS: C07K-016/00A; A61K-039/395B; A61K-051/10B

4/3/12 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126030350 CA: 126(3)30350b PATENT
Human antibodies derived from immunized xenomice
INVENTOR(AUTHOR): Kucherlapati, Raju; Jakobovits, Aya; Klapholz, Sue;
Brenner, Daniel G.; Capon, Daniel J.
LOCATION: USA
ASSIGNEE: Cell Genesys, Inc.
PATENT: PCT International ; WO 9633735 A1 DATE: 19961031
APPLICATION: WO 96US5928 (19960429) *US 430938 (19950427)
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/00A; C07K-016/18B; C12N-005/16B; C12N-015/13B
DESIGNATED COUNTRIES: AU; CA; HU; JP; KR; NO; NZ DESIGNATED REGIONAL: AT

; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

4/3/13 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

119158224 CA: 119(15)158224m PATENT
Fluorescent monoclonal antibodies for flow cytometric classification and monitoring of leukemias
INVENTOR(AUTHOR): Terstappen, Leon W. M. M.
LOCATION: USA
ASSIGNEE: Becton, Dickinson and Co.
PATENT: United States ; US 5234816 A DATE: 930810
APPLICATION: US 731217 (910712)
PAGES: 36 pp. CODEN: USXXAM LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007240; G01N-033/536A; G01N-021/64B; G01N-033/574B

? ds

Set	Items	Description
S1	348	(SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR RITUXIMAB OR CD20)(10N)(ANTIBOD?)
S2	244	S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR NEOPLAS? OR LYMPHOMA? OR LEUKEMI?)
S3	216	RD S2 (unique items)
S4	13	S3 AND PY<2001

? ds

Set	Items	Description
S1	348	(SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR RITUXIMAB OR CD20)(10N)(ANTIBOD?)
S2	244	S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR NEOPLAS? OR LYMPHOMA? OR LEUKEMI?)
S3	216	RD S2 (unique items)
S4	13	S3 AND PY<2001

? ds

Set	Items	Description
S1	348	(SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR RITUXIMAB OR CD20)(10N)(ANTIBOD?)
S2	244	S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR NEOPLAS? OR LYMPHOMA? OR LEUKEMI?)
S3	216	RD S2 (unique items)
S4	13	S3 AND PY<2001

? ds

Set	Items	Description
S1	348	(SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR RITUXIMAB OR CD20)(10N)(ANTIBOD?)
S2	244	S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR NEOPLAS? OR LYMPHOMA? OR LEUKEMI?)
S3	216	RD S2 (unique items)
S4	13	S3 AND PY<2001

?
PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES
? ds

Set	Items	Description
S1	348	(SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR RITUXIMAB OR CD20)(10N)(ANTIBOD?)

```
S2        244   S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR NEOPLAS?
                OR LYMPHOMA? OR LEUKEMI?)
S3        216   RD S2  (unique items)
S4         13   S3 AND PY<2001
? ds

Set     Items   Description
S1        348   (SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR RITUXIMAB
                OR CD20)(10N)(ANTIBOD?)
S2        244   S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR NEOPLAS?
                OR LYMPHOMA? OR LEUKEMI?)
S3        216   RD S2  (unique items)
S4         13   S3 AND PY<2001
? t s4/7/1-12

 4/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

13701505   BIOSIS NO.: 199799335565
Increased inhibition of proliferation of human B cell lymphomas
  following ligation of CD40, and either CD19, CD20, CD95 or surface
  immunoglobulin
AUTHOR: Benoit Nicole E; Wade William F (Reprint)
AUTHOR ADDRESS: Dep. Microbiol., Dartmouth Med. Sch., Lebanon, NH 03756,
  USA**USA
JOURNAL: Immunopharmacology  35 (2): p129-139 1996 1996
ISSN: 0162-3109
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Non-Hodgkin's (NHL) B cell lymphomas are growth-inhibited
  by ligation of their CD40 molecules. This inhibition is not absolute in
  that apprxeq 50% of the cells are not inhibited. We conducted studies to
  see if other signals that have been reported to inhibit B cell
  lymphoma growth could be used in combination with anti-CD40
  signaling to completely inhibit growth. Ligation of surface
  immunoglobulin (Ig), CD19, CD20, CD37 or CD95 with soluble
    ***antibody***   did not affect growth of the panel of NHL cells examined.
  Ligation of CD20, CD19 or CD95 was inhibitory for some NHL cell lines if
  the primary antibody was crosslinked with a secondary
    ***antibody***  . Combining anti-  ***CD40***   with anti-CD19, anti-
***CD20***
  , or anti-Ig resulted in increased inhibition past that produced by anti-
    ***CD40***   alone. The additive effect of anti-  ***CD40***   and other
  antibodies to selected surface markers was not observed in all NHL
  cell lines. Crosslinking of CD95 was also growth inhibitory for the
  majority of the NHL, and when combined with anti-CD40 under conditions
  that afforded crosslinking of the two receptors, increased inhibition was
  seen in three of the NHL cell lines. We found that cAMP or sodium
  butyrate (NaB) were also effective at inhibiting growth of the NHL cells;
  this was a profound inhibition (approaching 100%) compared to the 50%
  inhibition seen with anti-CD40 treatment. The potential for anti-CD40 and
  either cAMP or NaB to be additive was tested and not found to be the
  case. The ability to inhibit proliferation of the NHL was very dynamic
  with some antibody combinations being either inhibitory for multiple
  cells, not having an effect at all, or in some cases being stimulatory.
  This suggests that the NHL may represent unique stages of B cells that
  might serve as a model system which could be developed to precisely
  categorize patient NHL.
```

4/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13374972 BIOSIS NO.: 199699009032
Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas
AUTHOR: Funakoshi Satoshi; Longo Dan L; Murphy William J (Reprint)
AUTHOR ADDRESS: Biological Carcinogenesis and Development Program, SAIC Frederick, Build. 567, Room 141, Frederick, MD 21702-1201, USA**USA
JOURNAL: Journal of Immunotherapy with Emphasis on Tumor Immunology 19 (2): p93-101 1996 1996
ISSN: 1067-5582
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The antitumor effects of CD40 and CD20 monoclonal antibodies (mAbs) were compared on various human B-cell ***lymphomas*** by using both in vitro and in vivo assays. Anti-CD40 directly inhibited the proliferation of human B-cell lymphomas in vitro, whereas anti-CD20 exerted no inhibitory effects on the growth of any ***lymphoma*** tested. These ***lymphomas*** were then injected into immunodeficient mice to examine the antitumor efficacy of these unconjugated mAbs in vivo. This xenogeneic model was used in the evaluation of various potential therapeutic agents against human ***cancers*** in an in vivo setting. Surprisingly, in contrast to its negligible effects on lymphoma growth in vitro, anti-CD20 was more efficacious than anti-CD40 in promoting the survival of mice bearing some but not all ***lymphoma*** lines. To determine whether the antitumor effects of these mAbs were direct or indirect in vivo, we concurrently treated tumor-bearing mice with mAbs to the murine Fc receptor to block antibody-dependent cell-mediated cytotoxicity (ADCC). When these neutralizing antibodies against Fc receptors were administered at the same time as mAb treatment, the antitumor effects of anti-CD20 in vivo were completely abrogated, whereas anti-CD40 treatment, although also diminished, still provided significant antitumor effects. These results indicate that the in vivo antitumor activity of the murine anti-human CD20 mAb was primarily due to ADCC by murine effector cells, which may not translate into comparable effects in humans. By contrast, anti-CD40 may be of potential clinical use in the treatment of lymphomas in humans because of its additional direct antiproliferative effects. The results also demonstrate a possible difficulty in accurately evaluating the potential clinical efficacy of murine antibodies against human ***tumors*** in a human/mouse model system. Murine monoclonal antihuman antibodies may produce greater effects in human/mouse xenogeneic models, in which they are more likely to elicit host effector systems than when used in vivo in humans.

4/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13000597 BIOSIS NO.: 199598468430
Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes

AUTHOR: Murphy William J (Reprint); Funakoshi Satoshi; Beckwith Margaret; Rushing Susan E; Conley Denise K; Armitage Richard J; Fanslow William C; Rager Helen C; Taub Dennis D; Ruscetti Francis W; Longo Dan L
AUTHOR ADDRESS: Biol. Carcinogenesis and Dev. Program, Program Resources Inc./DynCorp, NCI-FCRDC, Build. 567, Room 141, Frederick, MD 21702-1201, USA**USA
JOURNAL: Blood 86 (5): p1946-1953 1995 1995
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: CD40 is expressed on both normal and neoplastic B lymphocytes. Signal transduction through CD40 in vitro has been shown to exert stimulatory effects on normal B cells and inhibitory effects on Epstein-Barr virus (EBV)-induced B-cell lymphoma lines and some other cell lines derived from patients with aggressive histology ***lymphoma*** . The transfer of normal human peripheral blood lymphocytes (huPBL) from EBV-seropositive donors into severe combined immune deficient (SCID) mice has been previously shown to result in the generation of human B-cell ***lymphomas*** . These ***tumors*** are similar to the highly aggressive EBV-induced lymphomas that can arise clinically after transplantation or in the setting of immunodeficiency. Treatment of huPBL-SCID chimeric mice with anti-CD40 or anti-CD20 monoclonal antibodies (MoAb) significantly delayed the development of EBV-induced B-cell ***lymphoma*** . However, the effects of the two MoAb were mechanistically distinct. Anti-CD40 treatment prevented ***lymphoma*** generation, while still allowing for functional human B-cell engraftment in the huPBL-SCID mice compared with mice receiving no treatment, all of which succumbed to ***lymphoma*** . By contrast, treatment with anti-CD20 significantly inhibited total human B-cell engraftment in the SCID recipients, which accounted for the absence of ***lymphomas*** . In vitro assays examining the transformation of human B cells by EBV also indicated that anti-CD40 could directly inhibit EBV-transformation, whereas anti-***CD20*** ***antibodies*** had no effect. Thus, anti- ***CD40*** exerts selective effects to allow for the engraftment of normal human B cells and prevent the emergence of EBV ***lymphomas*** . Stimulation of CD40 by antibodies or its physiologic ligand may, therefore, be of significant clinical use in the prevention of EBV-induced B lymphomas that may arise when EBV-seropositive individuals receive immunosuppressive regimens after transplantation or in immune deficiency states, such as acquired immune deficiency syndrome.

4/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

10749007 BIOSIS NO.: 199191131898
DETECTION OF ACTIVATION ANTIGENS ON CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
AUTHOR: PALOCZI K (Reprint); POCSIK E; MIHALIK R; BENCZUR M; DEMETER J; SOLTI V; PETRANYI G; HOLLAN S R
AUTHOR ADDRESS: NATL INST HAEMATOLOGY BLOOD TRANSFUSION, BUDAPEST, PO BOX 44, H-1502, HUNGARY**HUNGARY
JOURNAL: Leukemia and Lymphoma 3 (1): p31-36 1990
ISSN: 1042-8194
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The peripheral blood mononuclear cells of patients with chronic lymphocytic leukaemia were characterized by the presence of a variety of cell surface differentiation antigens. The cells of 20 patients were found to be of B-cell phenotype when studied with antibodies directed against CD19, ***CD20*** , HLA-DR and sIg. Furthermore, a significant percentage of the cells gave a positive reaction with the monoclonal antibody to CD5. On the other hand, the CLL-cells did not express the CD21 antigen (C3d receptor, EBV receptor). We studied in parallel the presence of various activation antigens using 19 monoclonal antibodies grouped into 7 clusters (CD25, CD30, CD40, CD69, CD70 CD 39, CD71). A significantly higher percentage of the CLL cells expressed activation antigens than lymphocytes from healthy controls. The percentage of CD3/HLA+DR+cells, compared to the healthy control lymphocytes was not increased in the CLL patients, and the activated cells in CLL were found to have characteristics of B-cells. Based on these results, we suggest that the CLL cells, like the cells in Hodgkin's disease and T-cell lymphoma, are not resting, but activated B-cells or the ***neoplastic*** aberrants of activated cells.

4/7/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

0078467424 EMBASE No: 2001073341
Overview of idiopathic thrombocytopenic purpura: New approach to refractory patients
Bussel J.B.
Weill Med. College of Cornell University, Department of Pediatrics, Div. of Pediatric Hematol./Oncology, 525 E 68th St, New York, NY 10021, United States
CORRESP. AUTHOR/AFFIL: Bussel J.B.: Weill Med. College of Cornell University, Department of Pediatrics, Div. of Pediatric Hematol./Oncology, 525 E 68th St, New York, NY 10021, United States

Seminars in Oncology (Semin. Oncol.) (United States) December 1, 2000 , 27/6 SUPPL. 12 (91-98)
CODEN: SOLGA ISSN: 0093-7754
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 25

Idiopathic thrombocytopenic purpura is a disorder in which autoantibodies are made to platelets, resulting in accelerated platelet destruction. The diagnosis may be made in outpatients who are previously well or in patients with multiple medical conditions and medications. There are no unequivocal ways to distinguish immune thrombocytopenias from other thrombocytopenias, even with state-of-the-art tests including antiplatelet antibodies, thrombopoietin, glycocalicin, and platelet reticulocyte counts. Clinical evaluation includes ruling out a systemic process such as a viral infection or ***leukemia*** . Treatment of idiopathic thrombocytopenic purpura should be individualized. Substantial platelet increases are seen in more than 50% of patients who receive intravenous IgG, intravenous anti-D, steroids, or splenectomy. Two additional agents showing promising clinical trial experience are anti-CD40 ligand and rituximab (Rituxan; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA).

4/7/6 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

0076676499 EMBASE No: 1996352908
Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and iehter CD19, CD20, CD95 or surface immunoglobulin
Benoit N.E.; Wade W.F.
Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States
AUTHOR EMAIL: william.wade@dartmouth.edu
CORRESP. AUTHOR/AFFIL: Wade W.F.: Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, United States

Immunopharmacology (IMMUNOPHARMACOLOGY) (Netherlands) November 1, 1996 , 35/2 (129-139)
CODEN: IMMUD ISSN: 0162-3109
PUBLISHER ITEM IDENTIFIER: S0162310996001385
DOI: 10.1016/S0162-3109(96)00138-5
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 33

Non-Hodgkin's (NHL) B cell lymphomas are growth-inhibited by ligation of their CD40 molecules. This inhibition is not absolute in that ~50% of the cells are not inhibited. We conducted studies to see if other signals that have been reported to inhibit B cell lymphoma growth could be used in combination with anti-CD40 signaling to completely inhibit growth. Ligation of surface immunoglobulin (Ig), CD19, ***CD20*** , CD37 or CD95 with soluble antibody did not affect growth of the panel of NHL cells examined. Ligation of CD20, CD19 or CD95 was inhibitory for some NHL cell lines if the primary antibody was crosslinked with a secondary ***antibody*** . Combining anti- ***CD40*** with anti-CD19, anti- ***CD20*** , or anti-Ig resulted in increased inhibition past that produced by anti- ***CD40*** alone. The additive effect of anti- ***CD40*** and other antibodies to selected surface markers was not observed in all NHL cell lines. Crosslinking of CD95 was also growth inhibitory for the majority of the NHL, and when combined with anti-CD40 under conditions that afforded crosslinking of the two receptors, increased inhibition was seen in three of the NHL cell lines. We found that cAMP or sodium butyrate (NaB) were also effective at inhibiting growth of the NHL cells; this was a profound inhibition (approaching 100%) compared to the 50% inhibition seen with anti-CD40 treatment. The potential for anti-CD40 and either cAMP or NaB to be additive was tested and not found to be the case. The ability to inhibit proliferation of the NHL was very dynamic with some antibody combinations being either inhibitory for multiple cells, not having an effect at all, or in some cases being stimulatory. This suggests that the NHL may represent unique stages of B cells that might serve as a model system which could be developed to precisely categorize patient NHL.

4/7/7 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10283541 PMID: 1373168
IL-4 induces conformational change of CD20 antigen via a protein kinase C-independent pathway. Antagonistic effect of anti- ***CD40*** monoclonal ***antibody*** .

Dancescu M; Wu C; Rubio M; Delespesse G; Sarfati M
Notre-Dame Hospital, Research Center, University of Montreal, Quebec, Canada.
Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) Apr 15 1992, 148 (8) p2411-6, ISSN 0022-1767--Print Journal Code: 2985117R
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
The CD20 molecule is a unique phosphoprotein exclusively expressed on B cells during most stages of B cell ontogeny. We here report that rIL-4 down-regulates the expression of CD20 with anti-Leu-16 mAb (clone L27) on both unstimulated and anti-mu preactivated normal and leukemic B cells. None of the other recombinant lymphokines tested (IL-1, IL-2, IL-3, IL-6, IFN-alpha, and IFN-gamma, granulocyte/macrophage-CSF, transforming growth factor-beta, TNF-alpha, and lymphotoxin) decreased CD20 expression. Incubation of unstimulated or anti-mu preactivated B cells with IL-4 did not affect the steady state CD20 mRNA, suggesting that IL-4 exerted its effect mainly at a nontranscriptional level. Hence, IL-4 selectively down-regulates the CD20 epitope recognized by clone L27 without affecting seven other different epitopes, indicating that IL-4 acts by modifying the conformation of the CD20 molecule rather than by inhibiting its production or inducing its internalization. IL-4 most likely utilizes a protein kinase C-independent signal transduction pathway to modify CD20 molecule inasmuch as staurosporine, an inhibitor of protein kinase C, antagonizes phorbol esters (PMA) but not IL-4-induced CD20 down-regulation. In contrast, anti-CD40 mAb reverses the IL-4 but not the PMA inhibitory effect on CD20 expression. Given that CD20 may be part of a Ca2+ ion channel and plays a role in B cell activation and proliferation, it is proposed that the ability of anti-CD40 mAb to maintain the CD20 molecule in a given epitopic configuration on IL-4-stimulated B cells may be related to the long term proliferation of normal B cells that are strictly dependent on the presence of IL-4 and cross-linked anti-CD40 mAb for their continuous growth.
Record Date Created: 19920513
Record Date Completed: 19920513

4/7/8 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

130218273 CA: 130(17)218273r PATENT
Phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
INVENTOR(AUTHOR): Schieven, Gary L.
LOCATION: USA
ASSIGNEE: Bristol-Myers Squibb Company
PATENT: United States ; US 5877210 A DATE: 19990302
APPLICATION: US 465813 (19950605) *US 189330 (19940131)
PAGES: 73 pp., Cont.-in-part of U.S. Ser. Number 189,330. CODEN: USXXAM
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 514492000; A01N-055/02A; A61K-039/395B; C07F-053/00B
SECTION:
CA201006 Pharmacology
CA278XXX Inorganic Chemicals and Reactions
IDENTIFIERS: phosphotyrosine phosphatase inhibitor cell proliferation modulation, tyrosine kinase activator cell proliferation modulation, metab phosphotyrosine modulation immunomodulation, leukemia lymphoma

treatment phosphotyrosine metab modulation, B cell proliferation phosphotyrosine metab modulation, T cell proliferation phosphotyrosine metab modulation, signaling T cell phosphotyrosine metab modulation

DESCRIPTORS:

Leukemia inhibitors...
B cell leukemia inhibitors; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

Lymphoma inhibitors...
B cell; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

IgE... IgG1... IgG4... IgM...
B-cell class-switching prevention; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

Antiproliferative agents... Receptors...
B-cell; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

Antigens...
B87, monoclonal antibody to, conjugates with metal complexes; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

Antigens...
CDw75, monoclonal antibody to, conjugates with metal complexes; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

Antigens...
CDw78, monoclonal antibody to, conjugates with metal complexes; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

CD antigens...
CD24, monoclonal antibody to, conjugates with metal complexes; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

CD antigens...
CD37, monoclonal antibody to, conjugates with metal complexes; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

Drug resistance...
drug-resistant tumor cell lines; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

B cell leukemia... B cell lymphoma... T cell leukemia...
inhibitors; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

Keto-enol tautomers... 1,3-Diketones...
metal complexes; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

CD19(antigen)... CD20(antigen)... CD22(antigen)... CD40(antigen)...
CD80(antigen)... Complement receptor type 2...
monoclonal antibody to, conjugates with metal complexes; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

Apoptosis... B cell(lymphocyte)... CD28(antigen)... CD3(antigen)... Cell cycle... Class switching(immunoglobulin)... Colon carcinoma inhibitors... Eosinophil... Interleukin 2 receptors... Ionizing radiation... Leukemia inhibitors... Lung carcinoma inhibitors... Lymphocyte... Lymphoma inhibitors... Melanoma inhibitors... Monocyte... Neutrophil... Ovarian carcinoma inhibitors... Phosphorylation(biological)... pp60c-src protein... Radiosensitizers(biological)... Radiotherapy... Signal transduction(biological)... T cell(lymphocyte)... TCR(T cell receptors)...
phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation

Metabolism...
phosphotyrosine; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
Leukemia inhibitors...
T cell leukemia inhibitors; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
Monoclonal antibodies...
to B-cell receptors, conjugates with metal complexes; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
CAS REGISTRY NUMBERS:
7440-70-2 biological studies, phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
7440-50-8D 7440-55-3D 7440-62-2D complexes, phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
25464-02-2D 53295-03-7D 55173-45-0D 69594-30-5D 72074-54-5D 169291-77-4D conjugates with B-cell receptor binding partner, phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
23319-73-5D 62126-18-5D 68782-48-9D 68782-49-0D 68782-50-3D 68832-77-9D 68832-78-0D 169291-75-2D 169291-76-3D 169553-10-0D 221045-56-3D conjugates with B-cell receptor-binding monoclonal antibodies, phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
79747-53-8 80449-02-1 inhibitors; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
21820-51-9 metabolism; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
147-73-9D 304-88-1D 13246-32-7D molybdenum complexes, conjugates with B-cell receptor binding partner, phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
82707-54-8 monoclonal antibody to, conjugates with metal complexes; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
3153-26-2 9001-78-9 13395-16-9 14024-17-0 14284-89-0 14284-90-3 21679-31-2 33069-62-4 38213-69-3 138674-26-7 140208-17-9 141349-87-3 144697-17-6 phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
17216-08-9 27774-13-6 reaction; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
568-93-4D vanadium complexes, conjugates with B-cell receptor binding partners, Alizarin orange; phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
72-48-0D 80-71-7D 93-91-4D 117-39-5D 118-71-8D 119-53-9D 120-46-7D 123-54-6D 319-89-1D 326-06-7D 367-57-7D 458-37-7D 480-16-0D 499-44-5D 519-34-6D 528-21-2D 528-48-3D 529-44-2D 533-75-5D 552-86-3D 569-77-7D 583-80-2D 602-65-3D 626-53-9D 815-57-6D 874-23-7D 893-33-4D 1118-71-4D 1218-89-9D 1429-25-0D 1469-95-0D 1493-51-2D 1522-22-1D 1526-73-4D 1540-34-7D 1540-36-9D 1540-37-0D 1670-46-8D 1694-29-7D 1696-34-0D 2892-51-5D 3859-39-0D 4143-72-0D 4335-90-4D 4584-68-3D 6971-56-8D 7473-98-5D 15780-63-9D 16636-64-9D 17216-08-9D 17587-22-3D 18362-49-7D 18362-51-1D 21835-01-8D 23774-13-2D 25354-76-1D 26239-18-9D 27669-22-3D 27970-50-9D 30652-11-0D 36394-22-6D 51800-98-7D 56969-57-4D 57280-75-8D 57565-12-5D 58218-16-9D 71292-81-4D 82647-26-5D 84863-94-5D 90293-63-3D 97024-81-2D 104516-35-0D 118528-85-1D 198069-03-3D 220997-44-4D vanadium complexes, conjugates with B-cell receptor binding partners, phosphotyrosine phosphatase inhibitors or tyrosine kinase activators for controlling cellular proliferation
9025-75-6 1 and 2a; phosphotyrosine phosphatase inhibitors or tyrosine

kinase activators for controlling cellular proliferation

4/7/9 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

128166354 CA: 128(14)166354e PATENT
Improved method of treating immune cell mediated systemic diseases
INVENTOR(AUTHOR): Davis, Charles Baldwin; Bugelski, Peter John; MacDonald, Brian Richard
LOCATION: USA
ASSIGNEE: Smithkline Beecham Corpration; Davis, Charles Baldwin; Bugelski, Peter John; MacDonald, Brian Richard
PATENT: PCT International ; WO 9804281 A1 DATE: 19980205
APPLICATION: WO 97US12600 (19970725) *US 22472 (19960726)
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/00A; A61K-039/395B; C07K-014/00B; C07K-014/705B; C07K-016/00B
DESIGNATED COUNTRIES: JP; US DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
SECTION:
CA215002 Immunochemistry
IDENTIFIERS: immune cell surface antigen, systemic disease immune cell mediated
DESCRIPTORS:
Primate...
human chimeric antibody; T or B cell surface antigen-specific antibody or soluble antigen receptor or ligand for treating immune cell-mediated systemic diseases
Ligands...
soluble; T or B cell surface antigen-specific antibody or soluble antigen receptor or ligand for treating immune cell-mediated systemic diseases
Receptors...
surface antigen soluble receptor; T or B cell surface antigen-specific antibody or soluble antigen receptor or ligand for treating immune cell-mediated systemic diseases
Asthma... B cell lymphoma... B cell(lymphocyte)... CD20(antigen)... CD28(antigen)... CD40 ligand... CD40(antigen)... CD4(antigen)... CD80(antigen)... CD86(antigen)... CTLA-4(antigen)... Diseases(animal)... Graft vs. host reaction... Intramuscular injections... Intravenous injections... Lymphocyte... Monoclonal antibodies... Psoriasis... Rheumatoid arthritis... Surface antigens... T cell(lymphocyte)...
T or B cell surface antigen-specific antibody or soluble antigen receptor or ligand for treating immune cell-mediated systemic diseases

4/7/10 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126250224 CA: 126(19)250224d PATENT
Immunotherapeutic agents containing antibodies which specifically recognize a patient's class II antigens
INVENTOR(AUTHOR): Lindhofer, Horst; Thierfelder, Stefan
LOCATION: Germany,
ASSIGNEE: GSF - Forschungszentrum fuer Umwelt und Gesundheit Gmbh
PATENT: Germany Offen. ; DE 19531346 A1 DATE: 19970227
APPLICATION: DE 19531346 (19950825)
PAGES: 16 pp. CODEN: GWXXBX LANGUAGE: German

PATENT CLASSIFICATIONS:
CLASS: C07K-016/00A; A61K-039/395B; A61K-051/10B
SECTION:
CA215003 Immunochemistry
IDENTIFIERS: antibody class II antigen neoplasm immunotherapy
DESCRIPTORS:
Lymphoma inhibitors...
anaplastic large cell; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Enzymes,biological studies... Radionuclides... Superantigens... Toxins...
antibodies bound to; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Integrins...
antigens CD11; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Lymphoma inhibitors...
B-cell; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
CD antigens...
CD11; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
CD antigens...
CD24; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
CD antigens...
CD33; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Antigens...
CD41; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Antigens...
CD44v3; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Antigens...
CD44v6; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
CD45(antigen)...
CD45R; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
CD antigens...
CD6; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Langerhans' cell... Macrophage... Mast cell... Monocyte... Natural killer cell... Polymorphonuclear leukocyte... T cell(lymphocyte)...
effector cell; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Antitumor agents...
Hodgkin's disease inhibitors; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Liposomes(drug delivery systems)...
immunoliposomes; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Antibodies... Antigens... Antitumor agents... Autoimmunity... CD11b(antigen)... CD14(antigen)... CD19(antigen)... CD1(antigen)... CD20(antigen)... CD22(antigen)... CD28(antigen)... CD2(antigen)... CD3(antigen)... CD40(antigen)... CD45(antigen)... CD4(antigen)... CD56(antigen)... CD5(antigen)... CD7(antigen)... CD8(antigen)... Class II MHC antigens... Complement receptor type 2... Epithelium... FcγRI receptors... FcγRII receptors... FcγRIII receptors... FcεRII receptors... Graft-vs.-host reaction... Hematopoietic precursor cell... Idiotypes(immunoglobulin/TCR)... Immunoglobulin fragments

... Immunosuppression... Immunotherapy... Interleukin 2 receptors...
Interleukin 6 receptors... Tumor-associated antigen... Vascular endothelium
...
    immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
T-cell lymphoma...
    inhibitors, adult; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
B-cell lymphoma... Hodgkin's disease...
    inhibitors; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Antitumor agents...
    myeloma; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
Lymphoma inhibitors...
    T-cell lymphoma inhibitors, adult; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
  CAS REGISTRY NUMBERS:
588-55-3 antibodies bound to; immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens
90546-31-3 827075-48-3 immunotherapeutic antitumor agents containing antibodies which specifically recognize a patient's class II antigens

 4/7/11   (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

  126250223   CA: 126(19)250223c   PATENT
  Antibodies with two or more specificities for the selective elimination of tumor cells in vivo
  INVENTOR(AUTHOR): Lindhofer, Horst; Thierfelder, Stefan
  LOCATION: Germany,
  ASSIGNEE: GSF - Forschungszentrum fuer Umwelt und Gesundheit Gmbh
  PATENT: Germany Offen. ; DE 19531348 A1 DATE: 19970227
  APPLICATION: DE 19531348 (19950825)
  PAGES: 17 pp. CODEN: GWXXBX LANGUAGE: German
  PATENT CLASSIFICATIONS:
    CLASS: C07K-016/00A; A61K-039/395B; A61K-051/10B
  SECTION:
    CA215003 Immunochemistry
  IDENTIFIERS: antibody multispecificity tumor cell deletion
  DESCRIPTORS:
Enzymes,biological studies... Radionuclides... Superantigens... Toxins...
    antibodies bound to; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Integrins...
    antigens CD11; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Lymphoma inhibitors...
    B-cell; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
CD antigens...
    CD11; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
CD antigens...
    CD24; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
CD antigens...

CD33; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Antigens...
CD41; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Antigens...
CD44v3; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Antigens...
CD44v6; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
CD antigens...
CD6; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Carcinoma inhibitors...
colorectal and ovarian; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Antigens...
C215; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
B-cell lymphoma...
inhibitors; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Antigens...
L6; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Transferrins...
melanotransferrins; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Antibodies... Antigens... Antitumor agents... Breast carcinoma inhibitors
... CA 125(carbohydrate antigen)... CD14(antigen)... CD19(antigen)...
CD1(antigen)... CD20(antigen)... CD22(antigen)... CD28(antigen)...
CD2(antigen)... CD3(antigen)... CD40(antigen)... CD45(antigen)...
CD4(antigen)... CD5(antigen)... CD7(antigen)... CD8(antigen)... Class II
MHC antigens... Complement receptor type 2... FcγRI receptors...
FcγRII receptors... FcγRIII receptors... FcεRII
receptors... Glioblastoma inhibitors... Idiotypes(immunoglobulin/TCR)...
Immunotherapy... Leukemia inhibitors... Melanoma inhibitors...
Neuroblastoma inhibitors... Tumor-associated antigen... 17-1A antigen...
multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Antigens...
NE150; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
neu(receptor)...
p185neu; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
Antigens...
9.2.27; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
CAS REGISTRY NUMBERS:
588-55-3 antibodies bound to; multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo
90546-31-3 620103-71-3 659887-18-3 827075-48-3 multispecific antibodies to tumor-associated antigens and cell surface antigens for selective elimination of tumor cells in vivo

4/7/12 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126030350 CA: 126(3)30350b PATENT
Human antibodies derived from immunized xenomice
INVENTOR(AUTHOR): Kucherlapati, Raju; Jakobovits, Aya; Klapholz, Sue; Brenner, Daniel G.; Capon, Daniel J.
LOCATION: USA
ASSIGNEE: Cell Genesys, Inc.
PATENT: PCT International ; WO 9633735 A1 DATE: 19961031
APPLICATION: WO 96US5928 (19960429) *US 430938 (19950427)
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/00A; C07K-016/18B; C12N-005/16B; C12N-015/13B
DESIGNATED COUNTRIES: AU; CA; HU; JP; KR; NO; NZ DESIGNATED REGIONAL: AT ; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
SECTION:
CA215003 Immunochemistry
IDENTIFIERS: human antibody transgenic animal, xenomice human monoclonal antibody antigen
DESCRIPTORS:
Integrins...
αRβ3; human antibodies derived from immunized xenomice
Integrin αv... Integrin β1... Integrins...
αvβ1; human antibodies derived from immunized xenomice
Integrin αv... Integrins...
αvβ5; human antibodies derived from immunized xenomice
Integrins...
αVβ6; human antibodies derived from immunized xenomice
Integrins...
αVβ7; human antibodies derived from immunized xenomice
Glycoproteins(specific proteins and subclasses)...
Amadori reaction products; human antibodies derived from immunized xenomice
Antigens...
A7; human antibodies derived from immunized xenomice
Interferon receptors...
β; human antibodies derived from immunized xenomice
Antigens...
B7.3; human antibodies derived from immunized xenomice
Tetanus toxin...
C; human antibodies derived from immunized xenomice
CD antigens...
CDw52; human antibodies derived from immunized xenomice
CD antigens...
CD27; human antibodies derived from immunized xenomice
CD antigens...
CD6; human antibodies derived from immunized xenomice
CD antigens...
CD72; human antibodies derived from immunized xenomice
Glycoprotein B... Glycoprotein H...
cytomegalovirus; human antibodies derived from immunized xenomice
Sialoglycoproteins...
endosialins; human antibodies derived from immunized xenomice
Cytokines...
fibrosin; human antibodies derived from immunized xenomice
Gangliosides...
GB2; human antibodies derived from immunized xenomice
Glycoproteins(specific proteins and subclasses)...
gcIII, cytomegalovirus; human antibodies derived from immunized

xenomice
Lipids,biological studies...
glycated; human antibodies derived from immunized xenomice
Cytomegalovirus...
glycoproteins; human antibodies derived from immunized xenomice
Genes(animal)...
GROα, products; human antibodies derived from immunized xenomice
Genes(animal)...
GROβ, products; human antibodies derived from immunized xenomice
Myelin...
growth inhibitor associated with; human antibodies derived from immunized
xenomice
Surface antigens...
hepatitis virus; human antibodies derived from immunized xenomice
Allergens... Animal cell line... Animal cells... Antibodies... Antigens...
Carcinoembryonic antigen... CD11a(antigen)... CD11b(antigen)...
CD11c(antigen)... CD14(antigen)... CD19(antigen)... CD20(antigen)...
CD22(antigen)... CD28(antigen)... CD2(antigen)... CD30(antigen)...
CD3(antigen)... CD40(antigen)... CD44(antigen)... CD45(antigen)...
CD4(antigen)... CD56(antigen)... CD5(antigen)... CD69(antigen)...
CD7(antigen)... CD80(antigen)... CD86(antigen)... CD8(antigen)... Cell
adhesion molecules... Chemokines... Cholesteryl ester transfer protein...
Class I MHC antigens... Class II MHC antigens... Coagulation factors(blood)
... CTLA-4(antigen)... Dermatophagoides... E glycoprotein(envelope
glycoprotein)... Endotoxins... Enzymes,biological studies... Eosinophil
cationic protein... Epidermal growth factor receptors... Erythropoietin
receptors... E-selectin... Fas antigen... Fc receptors... FcεRI
receptors... FcεRII receptors... Fibrinogens... Fibrins...
Fibroblast growth factor receptors... Genes(animal)... Granulocyte
colony-stimulating factor receptors... Growth factors(animal)...
Hematopoietin receptors... Hepatitis virus... Histocompatibility antigens
... Human herpesvirus... Human immunodeficiency virus 1... Human
papillomavirus... ICAM-1(cell adhesion molecule)... ICAM-2(cell adhesion
molecule)... IgE... Immunoglobulins... Integrin αIIbβ3...
Integrin αvβ3... Integrin α1β1... Integrin
α2β1... Integrin α3β1... Integrin α4β1...
Integrin α5β1... Integrin α6β1... Integrin
α6β4... Integrin β1... Integrin β2... Integrins...
Interferon receptors... Interferon α receptors... Interferon γ
receptors... Interleukin 1 receptors... Interleukin 10... Interleukin 11...
Interleukin 12... Interleukin 13... Interleukin 15... Interleukin 1...
Interleukin 2 receptors... Interleukin 2... Interleukin 3 receptors...
Interleukin 3... Interleukin 4 receptors... Interleukin 4... Interleukin 5
receptors... Interleukin 5... Interleukin 6 receptors... Interleukin 6...
Interleukin 7 receptors... Interleukin 7... Interleukin 8 receptors...
Interleukin 8... Interleukin 9... Interleukins... Ley antigen...
LFA-1(antigen)... LFA-3(antigen)... L-selectin... Macrophage inflammatory
protein 1α... Mac-1 antigen... Major basic protein... Monoclonal
antibodies... Monocyte chemoattractant protein-1... Mucins...
Neutrophil-activating peptide-2... Osteopontin... Oxidized low-density
lipoproteins... Platelet-derived growth factor receptors...
Platelet-derived growth factors... Pseudomonas... p150,95 antigen...
P-glycoproteins... P-selectin... RANTES(chemokine)... Respiratory syncytial
virus... Rh blood groups... Selectins... TCR(T-cell receptors)...
Thyrotropin receptors... Toxins... Transforming growth factors β...
Tumor necrosis factor receptors... Tumor necrosis factor α...
Tumor-associated antigen... Type IV collagen... VCAM-1(cell adhesion
molecule)... Venoms...
human antibodies derived from immunized xenomice
Laminins...
human; human antibodies derived from immunized xenomice

Parathyroid hormone receptors...
    humoral hypercalcemic factor; human antibodies derived from immunized xenomice
Interleukin receptors...
    interleukin 10 receptors; human antibodies derived from immunized xenomice
Interleukin receptors...
    interleukin 11 receptors; human antibodies derived from immunized xenomice
Interleukin receptors...
    interleukin 13 receptors; human antibodies derived from immunized xenomice
Interleukin receptors... Interleukins...
    interleukin 14; human antibodies derived from immunized xenomice
Interleukin receptors...
    interleukin 15 receptors; human antibodies derived from immunized xenomice
Interleukin receptors...
    interleukin 9 receptors; human antibodies derived from immunized xenomice
Interferons...
    λ; human antibodies derived from immunized xenomice
Genes...
    library, Ig.; human antibodies derived from immunized xenomice
Membrane proteins...
    LMP-2 (latent-infection membrane protein 2); human antibodies derived from immunized xenomice
Allergens...
    Lol p I (Lolium perenne, I); human antibodies derived from immunized xenomice
Leukocyte...
    markers; human antibodies derived from immunized xenomice
Animal...
    nonhuman; human antibodies derived from immunized xenomice
Antibodies...
    perinuclear anticytoplasmatic antibodies or pANCA; human antibodies derived from immunized xenomice
c-erbB2 gene(animal)...
    products; human antibodies derived from immunized xenomice
Virus...
    protein; human antibodies derived from immunized xenomice
Interleukin 11... Interleukin 12... Interleukin 13... Interleukin 15...
Interleukin 9...
    receptors; human antibodies derived from immunized xenomice
DNA...
    recombinant; human antibodies derived from immunized xenomice
Receptors...
    RGFβ; human antibodies derived from immunized xenomice
Proteins(specific proteins and subclasses)...
    uropontins; human antibodies derived from immunized xenomice
Receptors... Receptors...
    vascular endothelial growth factor; human antibodies derived from immunized xenomice
Bee... Snake... Spider...
    venom; human antibodies derived from immunized xenomice
Proteins (general),biological studies...
    virus; human antibodies derived from immunized xenomice
Mouse...
    xeno- or transgenic; human antibodies derived from immunized xenomice
Latent membrane protein...
    1; human antibodies derived from immunized xenomice

```
Interleukin receptors...
    12; human antibodies derived from immunized xenomice
  CAS REGISTRY NUMBERS:
90027-15-3  90245-82-3  90546-31-3  372709-43-3  532375-95-3  620103-71-3
    620315-43-3  622295-09-3  800435-34-3  802954-38-3  802954-94-3
    816697-07-3  829868-98-3  924482-21-3  986038-40-3  1033708-61-3
    1162437-33-3  1232106-84-3  human antibodies derived from immunized
    xenomice
? ds

Set     Items   Description
S1        348   (SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR RITUXIMAB
              OR CD20)(10N)(ANTIBOD?)
S2        244   S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR NEOPLAS?
              OR LYMPHOMA? OR LEUKEMI?)
S3        216   RD S2  (unique items)
S4         13   S3 AND PY<2001
? s s1 and (sgn(w)40 or s2c6)
            348  S1
            754  SGN
        1682881  40
            136  SGN(W)40
             32  S2C6
     S5      18  S1 AND (SGN(W)40 OR S2C6)
? rd s5
     S6      13  RD S5  (unique items)
? t s6/7/all

 6/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0020917948   BIOSIS NO.: 200900258282
Preclinical Analysis of the Combined Activity of SGN-40, Anti-
  CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin
  Lymphoma
AUTHOR: Lewis Timothy S (Reprint); McCormick Renee S; McEarchern Julie A;
  Kissler Kim; Stone Ivan J; Gerber Hans-Peter; Drachman Jonathan G; Grewal
  Iqbal; Law Che-Leung
AUTHOR ADDRESS: Seattle Genet Inc, Mol Oncol and Immunol, Bothell, WA USA**
  USA
JOURNAL: Blood  112 (11): p561-562 NOV 16 2008 2008
CONFERENCE/MEETING: 50th Annual Meeting of the American-
Society-of-Hematology  San Francisco, CA, USA  December 06 -09, 2008;
20081206
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: SGN-40 is a humanized monoclonal antibody
  against CD40, a TNF receptor family member expressed in non-Hodgkin
  lymphoma (NHL), multiple myeloma, and several carcinomas.   ***SGN***  -
  40 is cytotoxic to NHL cell lines via activation of proapoptotic
  signal transduction pathways and mediates antibody dependent cellular
  cytotoxicity (ADCC) effector function activity. in this study we examined
  the anti-tumor activity of   ***SGN***  -  ***40***   in combination. with the
  anti-CD20 antibody, rituximab, in lymphoma cell line
  models. Cell proliferation data (H-3-thymidine incorporation assay) was
  generated for SGN-40 and rituximab alone and in combination
```

for three NHL cell lines (Ramos, RL, and SU-DHL4) and combination index (CI) analyses performed. SGN40 was reproducibly synergistic with rituximab in Ramos cells and additive in the RL and SU-DHL-4 cell lines in this assay. This suggested that different anti-proliferative signaling events are activated by these antibodies, which produce a greater anti-tumor effect when combined. To better understand the combined activity of SGN40 and rituximab, the signal transduction pathways activated by each ***antibody*** were examined. In Ramos cells ***SGN*** - 40 signaling caused the degradation of pro-survival BCL-6 oncoprotein and upregulation of TAp63a, a proapoptic p53 family member, while only BCL-6 degradation was triggered in the RI-and SU-DHL-4 cell lines. In contrast, rituximab signaling degraded BCL-6 protein in only one cell line (SU-DHL-4), and did not upregulate TAp63a expression in any of the cell lines examined. To further define the combined activity of SGN-40 with rituximab the effector function activity of both ***antibodies*** were examined in vitro. ADCC assays in the WIL2-S and Raji cell lines both showed a greater percent cell lysis in the presence of both SGN-40 and rituximab compared to either drug alone. Next, the ***SGN*** - ***40*** and rituximab were tested in subcutaneous mouse models of NHL to evaluate this combination in vivo. In a Ramos model, ***SGN*** - ***40*** and rituximab (dosed at 4.0mg/kg, q4dx4, ip) had significantly greater anti-tumor response when combined compared to the equivalent dose of either ***antibody*** alone. The anti-tumor response achieved with dual dosing of SGN-40 and rituximab was greater than the response expected if the combination was additive. Our data suggests that the improved efficacy of ***SGN*** - 40, rituximab combination therapy in vivo is due to distinct apoptotic signaling pathways activated by these two antibodies in addition to augmented effector function activity. The combination of SGN-40 and rituximab is currently being studied in clinical trials of NHL.

6/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0020855758 BIOSIS NO.: 200900196092
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia
AUTHOR: Lapalombella Rosa; Gowda Aruna; Joshi Trupti; Mehter Najma; Cheney Carolyn; Lehman Amy; Chen Ching-Shih; Johnson Amy J; Caligiuri Michael A; Tridandapani Susheela; Muthusamy Natarajan (Reprint); Byrd John C
AUTHOR ADDRESS: OSUCCC, 455E,410 W 12th Ave, Columbus, OH 43210 USA**USA
AUTHOR E-MAIL ADDRESS: raj.muthusamy@osumc.edu; john.byrd@osumc.edu
JOURNAL: British Journal of Haematology 144 (6): p848-855 MAR 2009 2009
ITEM IDENTIFIER: doi:10.1111/j.1365-2141.2008.07548.x
ISSN: 0007-1048
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Antibody-based therapies, such as rituximab and alemtuzumab, have contributed significantly to the treatment of Chronic Lymphocytic leukaemia (CLL). The CD40 antigen is expressed predominantly on B-cells and represents a potential target for immune-based therapies. SGN-40 is a humanized IgG1 monoclonal antibody currently in Phase I/II clinical trials for indolent lymphomas, diffuse large B cell lymphomas and Multiple Myeloma. Its biological effect on CLL cells has not been studied. The present study demonstrated that ***SGN***

-40 mediated modest apoptosis in a subset of patients with secondary cross-linking but did not mediate complement-dependent cytotoxicity. ***SGN*** - ***40*** also mediated ***antibody*** -dependent cellular cytotoxicity (ADCC) predominantly through natural killer (NK) cells. Previous studies by our group and others have demonstrated that lenalidomide upregulates CD40 expression on primary B CLL cells and activates NK-cells. We therefore examined for the combinatorial effect of lenalidomide and SGN-40 and demonstrated that both enhanced direct apoptosis and ADCC against primary CLL B cells. These data together provide justification for clinical trials of SGN-40 and lenalidomide in combination for CLL therapy.

6/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

00201706 75 BIOSIS NO.: 200800217614
The humanized anti-CD40 monoclonal antibody, SGN-40, potentiates chemotherapy regimens in NHL xenograft models via pro-apoptotic signaling
AUTHOR: Lewis Timothy S (Reprint); McCormick Renee S; Kissler Kim; Stone Ivan J; Jonas Mechthild; Sutherland May S K; Gerber Hans-Peter; Drachman Jonathan G; Grewal Iqbal S; Law Che-Leung
AUTHOR ADDRESS: Seattle Genet Inc, Bothell, WA USA**USA
JOURNAL: Blood 110 (11, Part 1): p692A-693A NOV 16 2007 2007
CONFERENCE/MEETING: 49th Annual Meeting of the American-Society-of-Hematology Atlanta, GA, USA December 08 -11, 2007; 20071208
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: SGN-40 is a humanized, antibody targeting CD40, a TNF receptor family member expressed on normal B cells, non-Hodgkin's lymphoma (NHL), multiple myeloma, and a variety of carcinomas. Previous studies have shown that ***SGN*** - ***40*** triggers proapoptotic signal, transduction, mediates effector function (ADCC), and has in vivo antitumor activity in CD40(+) lymphoma xenograft models. We now report in vivo efficacy data for SGN-40 in combination with the anti-CD20 monoclonal antibody, rituximab, and approved chemotherapy regimens for the treatment of NHL. The growth of subcutaneous Ramos tumors in SCID mice was delayed following SGN-***40*** or rituximab treatment. However, the combination of ***SGN*** - 40 + rituximab (S-R) significantly improved efficacy over either ***antibody*** alone. ***SGN*** - ***40*** was then tested with ICE (ifosfamide, carboplatin, etoposide) chemotherapy with or without rituximab (S-R-ICE and S-ICE). These studies demonstrated that both S-R-ICE and S-ICE treated mice had lower tumor burden than R-ICE or ***SGN*** - ***40*** treated animals. Additionally, the effect of ***SGN*** -40 in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy with or without rituximab (S-R-CHOP and S-CHOP) was examined. S-R-CHOP and S-CHOP therapies showed a significant delay in tumor growth compared with R-CHOP or SGN-***40*** alone. Furthermore, the efficacy observed in S-R-ICE and S-R-CHOP treatments exceeded the S-R combination, suggesting that SGN-40 chemosensitizes lymphoma cells by a signaling

mechanism in addition to augmenting ADCC when combined with rituximab. To better understand the chemosensitization effect of SGN-40 in xenograft models, signal transduction events triggered by SGN-***40*** were examined in vitro. ***SGN*** - ***40*** treatment caused the sustained degradation of the BCL-6 protooncogene in several lymphoma cell lines, following prolonged MAP Kinase pathway activation. BCL-6 is implicated in lymphomagenesis of germinal center derived lymphomas, and is proteasomally degraded after phosphorylation by ERK1/2 MAPK. Immunohistochemical analyses of Ramos tumors harvested from mice. following treatment with SGN-40 or S-CHOP revealed elevated numbers of apoptotic cells versus untreated tumors. A distinct downregulation of BCL-6 staining in Ramos tumor cells was also observed in SGN-40 and S-CHOP treated animals, correlating with increased cell death. Finally, in some NHL lines ***SGN*** - ***40*** upregulated the p53 family member TAp63alpha, a chemo-sensitizing transcription factor capable of inducing apoptosis when overexpressed. When combined with cytotoxic agents, SGN-40 caused a greater induction of TAp63alpha compared with chemotherapy alone, a potential mechanism underlying the improved antitumor activity seen in combination studies. Collectively, these data suggest that ***SGN*** - ***40*** signaling occurs at the tumor site, likely contributing directly to tumor cell killing and chemosensitization. These preclinical studies support our earlier work suggesting that addition of SGN-40 to standard therapeutic regimens may improve the outcome for patients with NHL.

6/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0019905925 BIOSIS NO.: 200700565666
New agents in development for non-Hodgkin's lymphoma
AUTHOR: Leonard John P (Reprint); Ruan Jia; Martin Peter; Coleman Morton; Furman Richard R
AUTHOR ADDRESS: Weill Cornell Med Coll, Ctr Lymphoma and Myeloma, Starr Bldg,Room 340,520 E 70th St, New York, NY 10021 USA**USA
AUTHOR E-MAIL ADDRESS: jpleonar@med.comell.edu
JOURNAL: Seminars in Hematology 44 (3, Suppl. 4): pS18-S21 JUL 2007 2007
ITEM IDENTIFIER: doi:10.1053/j.seminhematol.2007.06.005
ISSN: 0037-1963
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Since its introduction 10 years ago, the anti-CD20 monoclonal antibody rituximab has benefited numerous patients with non-Hodgkin's lymphoma (NHL). However, rituximab is not effective in all patients, and many patients who initially respond ultimately develop resistance. Several strategies have been implemented to improve upon the efficacy of rituximab, including radiolabeled anti-CD20 antibodies, second-generation engineered anti-CD20 antibodies with various potential improvements over rituximab , and novel monoclonal antibodies directed against other B-cell antigens. This review describes results from early clinical trials in lymphoma patients for many of these new agents, including the anti-CD20 antibodies ofatumumab and hA20, the anti-CD22 antibodies epratuzumab and CIVIC-544, the anti-CD80 antibody galiximab, and the anti-CD40 ***antibody*** ***SGN*** - ***40*** . These therapies are promising, and many are currently being evaluated with

rituximab in clinical trials to determine the optimal combination therapies for lymphoma patients.

6/7/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082842343 EMBASE No: 2009054579
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
Sikder M.A.; Friedberg J.W.
AUTHOR EMAIL: jonathan; friedberg@urmc.rochester.edu
CORRESP. AUTHOR/AFFIL: Friedberg J.W.: James P. Wilmot Cancer Center, Division of Hematology-Oncology, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, United States
CORRESP. AUTHOR EMAIL: jonathan; friedberg@urmc.rochester.edu

Current Hematologic Malignancy Reports (Curr. Hematol. Malig. Rep.) (United States) December 1, 2008, 3/4 (187-193)
ISSN: 1558-8211 eISSN: 1558-822X
DOI: 10.1007/s11899-008-0027-5
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 37

The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies. The goal of these newer agents is to achieve similar or better response rates as seen with rituximab and perhaps demonstrate activity in rituximab -refractory disease. Several of the ***antibodies*** have been investigated in combination with each other as well as with conventional chemotherapeutic regimens. Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials. (c) Current Medicine Group LLC 2008.

6/7/6 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082814332 EMBASE No: 2009012194
Treatment of chronic lymphoid leukemias with monoclonal antibodies: Current place and perspectives
ISSUE TITLE: New Cancer Drugs, Part II
Robak T.
Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland; Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2, 93-510 Lodz, Poland
AUTHOR EMAIL: robaktad@csk.umed.lodz.pl
CORRESP. AUTHOR/AFFIL: Robak T.: Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2, 93-510 Lodz, Poland
CORRESP. AUTHOR EMAIL: robaktad@csk.umed.lodz.pl

Drug Development Research (Drug Dev. Res.) (United States) November 1, 2008, 69/7 (373-387)

CODEN: DDRED ISSN: 0272-4391 eISSN: 1098-2299
DOI: 10.1002/ddr.20269
URL:
http://www3.interscience.wiley.com/cgi-bin/fulltext/121584500/PDFSTART
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 113

Over the past few years, several monoclonal antibodies (MAbs) directed against lymphoid cells have been developed and investigated in preclinical studies and clinical trials. Some of them are highly active in leukemias. At present, the most important clinical value in the patients with chronic lymphocytic leukemia (CLL) has two MAbs. The first is the human mouse antibody, rituximab (IDEC C2B8, Rituxan, Mabthera), which targets ***CD20*** antigen. The second is alemtuzumab (Campath-1H), a humanized form of a rat antibody active against CD52. Recently, several new MAbs have been explored and have shown promise in treating CLL. Novel MAbs are being evaluated in preclinical studies and in early clinical trials. These treatments include new MAbs targeted CD20 molecule (ofatumumab, GA-101), lumiliximab, epratuzumab, apolizumab, galiximab, and anti-CD40 MAbs. Alemtuzumab is also a useful drug in previously treated and untreated patients with T-cell prolymphocytic leukemia. Rituximab as well as anti-CD22 and anti-CD25 immunotoxins have been also investigated in refractory and/or relapsed hairy cell leukemia with high response rate. MAbs provided new opportunities for effective therapies of these disorders.

6/7/7 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

0082695036 EMBASE No: 2008497012
New monoclonal antibodies for non-Hodgkin's lymphoma
ISSUE TITLE: 10th International Conference on Malignant Lymphoma
Leonard J.P.; Martin P.; Ruan J.; Elstrom R.; Barrientos J.; Coleman M.; Furman R.R.
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, New York Presbyterian Hospital, New York, NY, United States
CORRESP. AUTHOR/AFFIL: Leonard J.P.: Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, New York Presbyterian Hospital, New York, NY, United States

Annals of Oncology (Ann. Oncol.) (United Kingdom) June 1, 2008, 19/SUPPL. 4 (iv60-iv62)
CODEN: ANONE ISSN: 0923-7534 eISSN: 1569-8041
DOI: 10.1093/annonc/mdn199
DOCUMENT TYPE: Journal; Article RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 15

6/7/8 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE

0082315872 EMBASE No: 2008117923
Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia
Robak T.
Department of Hematology, Medical University of Lodz, Copernicus Memorial

Hospital, ul. Ciolkowskiego 2, 93-510 Lodz, Poland
AUTHOR EMAIL: robaktad@csk.umed.lodz.pl
CORRESP. AUTHOR/AFFIL: Robak T.: Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, ul. Ciolkowskiego 2, 93-510 Lodz, Poland
CORRESP. AUTHOR EMAIL: robaktad@csk.umed.lodz.pl

Current Cancer Drug Targets (Curr. Cancer Drug Targets) (Netherlands) March 1, 2008, 8/2 (156-171)
CODEN: CCDTB ISSN: 1568-0096
DOI: 10.2174/156800908783769319
URL: http://docstore.ingenta.com/cgi-bin/deliver/1/u/d/ISIS/42742452.1/ben/ccdt/2008/00000008/00000002/art00010/7AA5B3460F9F307E1204693450669F3A4EDBC94253.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 134

For many years, alkylating agents and purine nucleoside analogs (PNA) have been considered the drug of choice for treatment of chronic lymphocytic leukemia (CLL). More recently the introduction of monoclonal antibodies (mAb), especially rituximab directed against CD20 and alemtuzumab directed against CD52, has renewed interest in CLL therapy. Over the last few years, several new mAbs directed against lymphoid cells have been developed and investigated in preclinical studies and clinical trials. Some of them are highly active in CLL. New mAbs directed against CD20 include human mAb ofatumumab (HuMax CD20) , IMMU-106 (hA20) which has a >90% humanized framework and GA-101, a novel third - generation fully humanized and optimized mAb. These agents are highly cytotoxic against B-cell lymphoid cells and are evaluated in CLL. Lumiliximab (anti-CD23 mAb) is a genetically engineered macaque-human immunoglobulin (Ig) A1. This antibody showed high activity and good tolerability in phase I clinical trial and is evaluated in phase I/II clinical trials as a single agent and in combination. Epratuzumab is a humanized anti-CD22 mAb currently used in clinical trials for treatment of non-Hodgkin lymphoma and autoimmune disorders. Further studies are needed to elucidate the role of this agent in CLL. Apolizumab (HU1D10) is a humanized IgG1 antibody specific for a polymorphic determinant found on the HLA-DRbeta chain. Preclinical and early clinical studies suggest that this mAb has some activity in CLL. HCD122 (CHIR-12.12) and ***SGN*** - ***40*** are anti-CD40 mAbs which induce cytotoxicity against CLL cells. Phase I study has shown a favorable safety profile and some activity of HCD122 in pretreated CLL patients. Immunotoxins, especially BL22, LMP-2 and denileukin diftitox, are also being evaluated in lymphoid malignancies and seem to be active in CLL. Finally, antiangiogenic mAbs, especially bevacimzumab, have a potential therapeutic role in this disease. In this review, new mAbs, potentially useful in CLL are presented. (c) 2008 Bentham Science Publishers Ltd.

6/7/9 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE

0082049750 EMBASE No: 2007484256
Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma
Martin P.; Furman R.R.; Coleman M.; Leonard J.P.
Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, United States

AUTHOR EMAIL: jpleonar@med.cornell.edu
CORRESP. AUTHOR/AFFIL: Leonard J.P.: Weill Medical College of Cornell University, New York Presbyterian Hospital, Starr Building, 520 East 70th Street, New York, NY 10021, United States
CORRESP. AUTHOR EMAIL: jpleonar@med.cornell.edu

Clinical Cancer Research (Clin. Cancer Res.) (United States) September 15, 2007, 13/18 (5636s-5642s)
CODEN: CCREF ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-07-1085
URL: http://clincancerres.aacrjournals.org/cgi/reprint/13/18/5636s
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 77

Led by the anti-CD20 antibody rituximab, therapeutic monoclonal antibodies have dramatically altered the treatment of patients with non-Hodgkin's lymphoma. As the understanding of the biology of this novel therapy improves, so does the potential for further progress. There are currently four monoclonal antibodies approved by the Food and Drug Administration for the treatment of B-cell malignancies and dozens more are in various stages of development. The indications for the currently available antibodies, both labeled and unlabeled, are being expanded to include first-line treatment, maintenance strategies, and combinations with chemotherapy. Newer agents are being engineered to target novel antigens, and to interact more specifically with the host immune system. These promising therapeutics face a significant challenge in evaluation and integration in the post-rituximab world. (c) 2007 American Association for Cancer Research.

6/7/10 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE

0081704985 EMBASE No: 2007138623
Monoclonal antibodies in the treatment of non-hodgkin's lymphoma
Fanale M.A.; Younes A.
Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, United States; Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009, United States
AUTHOR EMAIL: mfanale@mdanderson.org
CORRESP. AUTHOR/AFFIL: Fanale M.A.: Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009, United States
CORRESP. AUTHOR EMAIL: mfanale@mdanderson.org

Drugs (Drugs) (New Zealand) April 3, 2007, 67/3 (333-350)
CODEN: DRUGA ISSN: 0012-6667 eISSN: 0012-6667
DOI: 10.2165/00003495-200767030-00002
URL:
http://drugs.adisonline.com/pt/re/drugs/pdfhandler.00003495-200767030-00002.pdf;jsessionid=F32hkjwgscJpLS6TzsVHknxJKpFXML71n2y8p17xMmmxwdJ0V5B1!-1633365230!-949856144!8091!-1
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 110

Antibody-based therapeutic approaches have had a significant impact in the treatment of non-Hodgkin's lymphoma (NHL). ***Rituximab*** 's development as an anti-CD20 antibody heralded a new era in

treatment approaches for NHL. While ***rituximab*** was first shown to be effective in the treatment of relapsed follicular lymphoma, it is now standard monotherapy for front-line treatment of follicular lymphoma, and is also used in conjunction with chemotherapy for other indolent, intermediate and aggressive B-cell lymphomas. The development of rituximab led to intense interest in this type of therapeutic approach and to development approval of the radioimmunoconjugates of rituximab, SUP 90Y-ibritumomab tiux etan and SUP 131I-tositumomab, which have added to the repertoire of treatments for relapsed follicular lymphoma and increased interest in developing other conjugated ***antibodies*** . Since rituximab is a chimeric antibody, there is a need to develop fully humanised antibodies, such as INMU-106 (hA20), in order to minimise infusion reactions and eliminate the development of human antibodies against the drug. Further clinical evaluation of antibodies has been based largely on our knowledge of antigen expression on the surface of lymphoma cells and has led to the development of antibodies against CD22 (unconjugated epratuzumab and calicheamicin conjugated CMC-544 [inotuzumab ozogamicin]), CD80 (galiximab), CD52 (alemtuzumab), CD2 (MEDI-507 [siplizumab]), CD30 (SGN-30 and MDX-060 [iratumumab]), and CD40 (SGN-***40***). Furthermore, the VEGF (vascular endothelial growth factor) inhibitor bevacizumab, which was first approved for the treatment of colon cancer is currently under investigation in NHL, and agonists rather than antibodies to TRAIL (tumour necrosis factor-related apoptosis-inducing ligand) [rApo2L/TRAIL, HGS-ETR1{mapatumumab}, HGS-ETR2] are currently being investigated as treatments for both advanced solid tumours and NHL. Knowledge of the ability of cancer cells to become resistant to a targeted therapy by activating an alternative pathway to evade apoptosis has driven studies that combine antibodies such as epratuzumab plus rituximab (ER) or ER plus chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) [ER-CHOP], inotuzumab ozogamicin plus rituximab, alemtuzumab plus CHOP (CHOP-C), bevacizumab plus rituximab, and now the combination of rApo2L/TRAIL plus rituximab. As a result of the expansion of research in this area, several treatment-specific adverse effects have been noted, including infusion-related reactions for rituximab, myelosuppression secondary to SUP 90Y- ibritumomab tiuxetan and SUP 131Itositumomab, and immunosuppression leading to infectious complications for alemtuzumab. Also, soluble forms of the antigens (sCD30) are now being investigated as potential mechanisms of resistance to antibody treatments by binding the antibody before the drug can bind to the lymphoma cell. In addition, it has also become apparent that these antibodies often have a dose-dependent half-life (rituximab) or long half-lives of up to 2-3 weeks (epratuzumab and galiximab) with a consequent delay to a response, thus influencing how long we should wait for a response before declaring an antibody to be ineffective. Antibody-based therapeutic approaches have already had a profound impact on the treatment of NHL, and it is almost certain that, as their clinical development progresses, we will continue to refine the optimum methods of incorporating these drugs in NHL treatment in order to offer our patients the best clinical benefits.

0081692249 EMBASE No: 2007125859
Role of monoclonal antibodies in tumor-specific immunity
Nicodemus C.F.; Smith L.M.; Schultes B.C.
Unither Pharmaceuticals, Inc., 15 Walnut Street, Wellesley Hills, MA 02481, United States; Clinical Research and Development, Unither

Pharmaceuticals, Inc., 15 Walnut Street, Wellesley Hills, MA 02481, United States
AUTHOR EMAIL: cnicodemus@unither.com; msmith@unither.com; bschultes@unither.com
CORRESP. AUTHOR/AFFIL: Nicodemus C.F.: Unither Pharmaceuticals, Inc., 15 Walnut Street, Wellesley Hills, MA 02481, United States
CORRESP. AUTHOR EMAIL: cnicodemus@unither.com

Expert Opinion on Biological Therapy (Expert Opin. Biol. Ther.) (United Kingdom) March 1, 2007, 7/3 (331-343)
CODEN: EOBTA ISSN: 1471-2598
DOI: 10.1517/14712598.7.3.331
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 92

Monoclonal antibodies, considered to be 'magic bullets' 20 years ago, may finally be realizing their full potential, particularly in the area of oncology, where > 10 monoclonal antibodies are approved for treatment. Monoclonal antibodies are being used to modulate tumor-specific immunity through several approaches: antibodies that direct cytotoxicity against the tumor through cellular or complement-mediated pathways; antibodies that directly modulate immune regulation; antibodies that alter tolerance to tumor antigens; and antibodies that act as antigen mimetics through the anti-idiotype network. Therapeutic progress in these areas is reviewed as well as the potential to combine these approaches with standard therapies. (c) 2007 Informa UK Ltd.

6/7/12 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE

0081440253 EMBASE No: 2006503327
Humanized antibodies elicit response in patients with lymphoma: Comment
Rosen S.T.
Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States
CORRESP. AUTHOR/AFFIL: Rosen S.T.: Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States

Oncology Report (Oncol. Rep.) (United States) September 1, 2006, -/FALL (76)
ISSN: 1548-5323 eISSN: 1548-5323
DOCUMENT TYPE: Journal; Note RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 2

6/7/13 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE

0081242139 EMBASE No: 2006304397
New drugs for chronic lymphocytic leukemia
Byrd J.
Department of Medicine and Medicinal Chemistry, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States
CORRESP. AUTHOR/AFFIL: Byrd J.: Department of Medicine and Medicinal Chemistry, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States

```
  Clinical Advances in Hematology and Oncology ( Clin. Adv. Hematol. Oncol.
  ) (United States)  March 1, 2006, 4/3 (183-185)
  ISSN: 1543-0790
  DOCUMENT TYPE: Journal; Note  RECORD TYPE: Citation
  LANGUAGE: English
  NUMBER OF REFERENCES: 4
? ds

Set     Items   Description
S1        348   (SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR RITUXIMAB
              OR CD20)(10N)(ANTIBOD?)
S2        244   S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR NEOPLAS?
              OR LYMPHOMA? OR LEUKEMI?)
S3        216   RD S2  (unique items)
S4         13   S3 AND PY<2001
S5         18   S1 AND (SGN(W)40 OR S2C6)
S6         13   RD S5  (unique items)
? ds

Set     Items   Description
S1        348   (SGN(W)40 OR CD40)(10N)(ANTIBOD?) AND (RITUXAN OR RITUXIMAB
              OR CD20)(10N)(ANTIBOD?)
S2        244   S1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGN? OR NEOPLAS?
              OR LYMPHOMA? OR LEUKEMI?)
S3        216   RD S2  (unique items)
S4         13   S3 AND PY<2001
S5         18   S1 AND (SGN(W)40 OR S2C6)
S6         13   RD S5  (unique items)
? s s3 and py>2007
           216  S3
       5240123  PY>2007
      S7    57  S3 AND PY>2007
? rd s7
      S8    57  RD S7  (unique items)
? t s8/3/all

 8/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0020917948   BIOSIS NO.: 200900258282
Preclinical Analysis of the Combined Activity of SGN-40, Anti-
  CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin
  Lymphoma
AUTHOR: Lewis Timothy S (Reprint); McCormick Renee S; McEarchern Julie A;
  Kissler Kim; Stone Ivan J; Gerber Hans-Peter; Drachman Jonathan G; Grewal
  Iqbal; Law Che-Leung
AUTHOR ADDRESS: Seattle Genet Inc, Mol Oncol and Immunol, Bothell, WA USA**
  USA
JOURNAL: Blood  112 (11): p561-562 NOV 16 2008 2008
CONFERENCE/MEETING: 50th Annual Meeting of the American-
Society-of-Hematology  San Francisco, CA, USA  December 06 -09, 2008;
20081206
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English
```

8/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0020855758 BIOSIS NO.: 200900196092
The humanized CD40 antibody SGN-40 demonstrates
pre-clinical activity that is enhanced by lenalidomide in chronic
lymphocytic leukaemia
AUTHOR: Lapalombella Rosa; Gowda Aruna; Joshi Trupti; Mehter Najma; Cheney
Carolyn; Lehman Amy; Chen Ching-Shih; Johnson Amy J; Caligiuri Michael A;
Tridandapani Susheela; Muthusamy Natarajan (Reprint); Byrd John C
AUTHOR ADDRESS: OSUCCC, 455E,410 W 12th Ave, Columbus, OH 43210 USA**USA
AUTHOR E-MAIL ADDRESS: raj.muthusamy@osumc.edu; john.byrd@osumc.edu
JOURNAL: British Journal of Haematology 144 (6): p848-855 MAR 2009
2009
ITEM IDENTIFIER: doi:10.1111/j.1365-2141.2008.07548.x
ISSN: 0007-1048
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0020787158 BIOSIS NO.: 200900127492
Treatment of Chronic Lymphoid Leukemias With Monoclonal Antibodies:
Current Place and Perspectives
AUTHOR: Robak Tadeusz (Reprint)
AUTHOR ADDRESS: Med Univ Lodz, Copernicus Mem Hosp, Dept Hematol,
Ciolkowskiego 2, PL-93510 Lodz, Poland**Poland
AUTHOR E-MAIL ADDRESS: robaktad@csk.umed.lodz.pl
JOURNAL: Drug Development Research 69 (7, Sp. Iss. SI): p373-387 NOV 2008
2008
ITEM IDENTIFIER: doi:10.1002/ddr.20269
ISSN: 0272-4391
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

8/3/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

0083187638 EMBASE No: 2009361204
Translational Mini-Review Series on B Cell-Directed Therapies: B
cell-directed therapy for autoimmune diseases
Hu C.; Wong F.S.; Wen L.
Department of Internal Medicine, School of Medicine, Yale University, 330
Cedar Street, New Haven, CT 06520, United States
AUTHOR EMAIL: li.wen@yale.edu
CORRESP. AUTHOR/AFFIL: Wen L.: Department of Internal Medicine, School of
Medicine, Yale University, 330 Cedar Street, New Haven, CT 06520, United
States
CORRESP. AUTHOR EMAIL: li.wen@yale.edu

Clinical and Experimental Immunology (Clin. Exp. Immunol.) (United
Kingdom) August 1, 2009, 157/2 (181-190)
CODEN: CEXIA ISSN: 0009-9104 eISSN: 1365-2249

DOI: 10.1111/j.1365-2249.2009.03977.x
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 106

8/3/5 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082991353 EMBASE No: 2009232053
New therapies for patients with chronic lymphocytic leukemia
Robak T.; Robak P.
Department of Hematology, Medical University of Lodz, ul. Ciolkowskiego 2, 93-510 Lodz, Poland
AUTHOR EMAIL: robaktad@csk.umed.lodz.pl
CORRESP. AUTHOR/AFFIL: Robak T.: Department of Hematology, Medical University of Lodz, ul. Ciolkowskiego 2, 93-510 Lodz, Poland
CORRESP. AUTHOR EMAIL: robaktad@csk.umed.lodz.pl

Current Cancer Therapy Reviews (Curr. Cancer Ther. Rev.) (Netherlands) December 1, 2008, 4/4 (235-242)
ISSN: 1573-3947
DOI: 10.2174/157339408786413380
URL: http://www.ingentaconnect.com/content/ben/cctr/2008/00000004/00000004/art00001
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 62

8/3/6 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082900018 EMBASE No: 2009132390
Flow cytometry can diagnose classical hodgkin lymphoma in lymph nodes with high sensitivity and specificity
Fromm J.R.; Thomas A.; Wood B.L.
Department of Laboratory Medicine, University of Washington, Seattle; University of Washington Medical Center, Box 357110, 1959 NE Pacific St, Seattle, WA 98195
CORRESP. AUTHOR/AFFIL: Fromm J. R.: University of Washington Medical Center, Box 357110, 1959 NE Pacific St, Seattle, WA 98195

American Journal of Clinical Pathology (Am. J. Clin. Pathol.) (United States) March 1, 2009, 131/3 (322-332)
CODEN: AJCPA ISSN: 0002-9173
DOI: 10.1309/AJCPW3UN9DYLDSPB
URL: http://ajcp.ascpjournals.org/content/131/3/322.full.pdf
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 35

8/3/7 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082842343 EMBASE No: 2009054579

Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
Sikder M.A.; Friedberg J.W.
AUTHOR EMAIL: jonathan; friedberg@urmc.rochester.edu
CORRESP. AUTHOR/AFFIL: Friedberg J.W.: James P. Wilmot Cancer Center, Division of Hematology-Oncology, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, United States
CORRESP. AUTHOR EMAIL: jonathan; friedberg@urmc.rochester.edu

Current Hematologic Malignancy Reports (Curr. Hematol. Malig. Rep.) (United States) December 1, 2008, 3/4 (187-193)
ISSN: 1558-8211 eISSN: 1558-822X
DOI: 10.1007/s11899-008-0027-5
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 37

8/3/8 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082760838 EMBASE No: 2008566020
Epstein-Barr virus in autoimmune diseases
Toussirot E.; Roudier J.
Department of Rheumatology, University Hospital Jean Minjoz, Besancon; and EA 3186 Agents Pathogenes et Inflammation, Besancon, France
AUTHOR EMAIL: etoussirot@chu-besancon.fr
CORRESP. AUTHOR/AFFIL: Toussirot E.: Department of Rheumatology, University Hospital Jean Minjoz, Besancon; and EA 3186 Agents Pathogenes et Inflammation, Besancon, France
CORRESP. AUTHOR EMAIL: etoussirot@chu-besancon.fr

Best Practice and Research: Clinical Rheumatology (Best Pract. Res. Clin. Rheumatol.) (United Kingdom) October 1, 2008, 22/5 (883-896)
CODEN: BPRCC ISSN: 1521-6942
PUBLISHER ITEM IDENTIFIER: S1521694208001046
DOI: 10.1016/j.berh.2008.09.007
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 59

8/3/9 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082695036 EMBASE No: 2008497012
New monoclonal antibodies for non-Hodgkin's lymphoma
ISSUE TITLE: 10th International Conference on Malignant Lymphoma
Leonard J.P.; Martin P.; Ruan J.; Elstrom R.; Barrientos J.; Coleman M.; Furman R.R.
Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, New York Presbyterian Hospital, New York, NY, United States
CORRESP. AUTHOR/AFFIL: Leonard J.P.: Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, New York Presbyterian Hospital, New York, NY, United States

Annals of Oncology (Ann. Oncol.) (United Kingdom) June 1, 2008, 19/SUPPL. 4 (iv60-iv62)

CODEN: ANONE ISSN: 0923-7534 eISSN: 1569-8041
DOI: 10.1093/annonc/mdn199
DOCUMENT TYPE: Journal; Article RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 15

8/3/10 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082681187 EMBASE No: 2008475748
Tolerance-inducing immunosuppressive strategies in clinical transplantation: An overview
Golshayan D.; Pascual M.
Transplantation Immunopathology Laboratory, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, Lausanne, Switzerland; Division of Nephrology, Transplantation Centre, CHUV, Lausanne, 1011, Switzerland
AUTHOR EMAIL: Dela.Golshayan@chuv.ch
CORRESP. AUTHOR/AFFIL: Golshayan D.: Division of Nephrology, Transplantation Centre, CHUV, Lausanne, 1011, Switzerland
CORRESP. AUTHOR EMAIL: Dela.Golshayan@chuv.ch

Drugs (Drugs) (New Zealand) November 13, 2008, 68/15 (2113-2130)
CODEN: DRUGA ISSN: 0012-6667 eISSN: 0012-6667
DOI: 10.2165/00003495-200868150-00004
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 126

8/3/11 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082626657 EMBASE No: 2008465442
Perspectives of systemic lupus erythematosus therapy
Borysewicz K.
Department of Rheumatology and Internal Diseases, Silesian Piasts University of Medicine, Borowska 213, 50-556 Wroclaw, Poland
AUTHOR EMAIL: krzysztof1964@poczta.onet.pl
CORRESP. AUTHOR/AFFIL: Borysewicz K.: Department of Rheumatology and Internal Diseases, Silesian Piasts University of Medicine, Borowska 213, 50-556 Wroclaw, Poland
CORRESP. AUTHOR EMAIL: krzysztof1964@poczta.onet.pl

Advances in Clinical and Experimental Medicine (Adv. Clin. Exp. Med.) (Poland) July 1, 2008, 17/4 (433-439)
CODEN: ACEMC ISSN: 1230-025X
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English; Polish
NUMBER OF REFERENCES: 40

8/3/12 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082604924 EMBASE No: 2008413322
Immunotherapy of type 1 diabetes

Li L.; Yi Z.; Tisch R.; Wang B.
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
AUTHOR EMAIL: rmtisch@med.unc.edu
CORRESP. AUTHOR/AFFIL: Tisch R.: Department of Microbiology and Immunology, Mary Ellen Jones Bldg., University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7290, United States
CORRESP. AUTHOR EMAIL: rmtisch@med.unc.edu

Archivum Immunologiae et Therapiae Experimentalis (Arch. Immunol. Ther. Exp.) (Switzerland) August 1, 2008, 56/4 (227-236)
CODEN: AITEA ISSN: 0004-069X eISSN: 1661-4917
DOI: 10.1007/s00005-008-0025-2
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 128

8/3/13 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082592096 EMBASE No: 2008332612
B-cell-targeted therapy for systemic lupus erythematosus: An update
Ding C.; Foote S.; Jones G.
Menzies Research Institute, University of Tasmania, Hobart, TAS, Australia; Menzies Research Institute, Private Bag 23, Hobart, TAS 7000, Australia
AUTHOR EMAIL: changhai.ding@utas.edu.au
CORRESP. AUTHOR/AFFIL: Ding C.: Menzies Research Institute, Private Bag 23, Hobart, TAS 7000, Australia
CORRESP. AUTHOR EMAIL: changhai.ding@utas.edu.au

BioDrugs (BioDrugs) (New Zealand) September 23, 2008, 22/4 (239-249)
CODEN: BIDRF ISSN: 1173-8804
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 79

8/3/14 (Item 11 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082578146 EMBASE No: 2008385086
Rituximab: Beyond simple B cell depletion
Kessel A.; Rosner I.; Toubi E.
Division of Clinical Immunology and Allergy, Bnai Zion Medical Center, Rappaport Faculty of Medicine, P.O.B. 4940, Haifa, Israel
AUTHOR EMAIL: elias.toubi@b-zion.org.il
CORRESP. AUTHOR/AFFIL: Toubi E.: Division of Clinical Immunology and Allergy, Bnai Zion Medical Center, Rappaport Faculty of Medicine, P.O.B. 4940, Haifa, Israel
CORRESP. AUTHOR EMAIL: elias.toubi@b-zion.org.il

Clinical Reviews in Allergy and Immunology (Clin. Rev. Allergy Immunol.) (United States) February 1, 2008, 34/1 (74-79)
CODEN: CRVAD ISSN: 1080-0549
DOI: 10.1007/s12016-008-8074-1
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 29

8/3/15 (Item 12 from file: 73)
DIALOG(R)File 73:EMBASE

0082574602 EMBASE No: 2008420409
Lymphoid malignancies: A decade and a half of dramatic improvements in outcome
Zelenetz A.D.

Clinical Lymphoma and Myeloma (Clin. Lymphoma Myeloma) (United States) August 1, 2008, 8/SUPPL. 4 (S126-S127)
ISSN: 1557-9190
DOI: 10.3816/CLM.2008.s.007
DOCUMENT TYPE: Journal; Editorial RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 11

8/3/16 (Item 13 from file: 73)
DIALOG(R)File 73:EMBASE

0082526258 EMBASE No: 2008328694
Emerging drugs for idiopathic thrombocytopenic purpura in adults
Li X.; Hou M.
Shandong University, Qilu Hospital, Department of Haematology, Jinan, Shandong, China
AUTHOR EMAIL: houming@medmail.com.cn
CORRESP. AUTHOR/AFFIL: Hou M.: Shandong University, Qilu Hospital, Department of Haematology, Jinan, Shandong, 250012, China
CORRESP. AUTHOR EMAIL: houming@medmail.com.cn

Expert Opinion on Emerging Drugs (Expert Opin. Emerg. Drugs) (United Kingdom) June 1, 2008, 13/2 (237-254)
CODEN: EOEDA ISSN: 1472-8214
DOI: 10.1517/14728214.13.2.237
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 100

8/3/17 (Item 14 from file: 73)
DIALOG(R)File 73:EMBASE

0082522132 EMBASE No: 2008294034
Advances in the treatment of aggressive non-Hodgkin's lymphomas
Postepy w leczeniu agresywnych chloniakolw nieziarniczych
Wrobel T.
Klinika Hematologii, Nowotworow Krwi I Transplantacji Szpiku AM we Wroclawiu; Klinika Hematologii, Nowotworow Krwi I Transplantacji Szpiku AM we Wroclawiu, ul. Pasteura 4, 50-367 Wroclaw
CORRESP. AUTHOR/AFFIL: Wrobel T.: Klinika Hematologii, Nowotworow Krwi I Transplantacji Szpiku AM we Wroclawiu, ul. Pasteura 4, 50-367 Wroclaw

Acta Haematologica Polonica (Acta Haematol. Pol.) (Poland) August 11, 2008, 39/2 (207-217)
CODEN: AHPLB ISSN: 0001-5814

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: Polish SUMMARY LANGUAGE: English; Polish
NUMBER OF REFERENCES: 42

8/3/18 (Item 15 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082473040 EMBASE No: 2008312638
Current and prospective treatment options for Sjogren,s syndrome
Sugai S.; Masaki Y.
Kudo General Hospital, Kanazawa Medical University, Kanazawa, Japan
AUTHOR EMAIL: sussugai@helen.ocn.ne.jp; yasum@kanazawa-med.ac.jp
CORRESP. AUTHOR/AFFIL: Sugai S.: Kudo General Hospital, Kanazawa University, Kanazawa, Japan
CORRESP. AUTHOR EMAIL: sussugai@helen.ocn.ne.jp

Expert Review of Clinical Immunology (Expert Rev. Clin. Immunol.) (United Kingdom) July 1, 2008, 4/4 (469-479)
ISSN: 1744-666X
DOI: 10.1586/1744666X.4.4.469
URL: http://www.expert-reviews.com/doi/pdf/10.1586/1744666X.4.4.469
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 87

8/3/19 (Item 16 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082368373 EMBASE No: 2008165232
New approaches of B-cell-directed therapy: Beyond rituximab
Dorner T.; Burmester G.R.
Charite Center 14, Charite University Hospital Berlin, Deutsche Rheumaforschungszentrum, Berlin, Germany; Charite University Hospital Berlin, Deutsches Rheumaforschungszentrum, Chariteplatz 01, 10098 Berlin, Germany
AUTHOR EMAIL: thomas.doerner@charite.de
CORRESP. AUTHOR/AFFIL: Dorner T.: Charite University Hospital Berlin, Deutsches Rheumaforschungszentrum, Chariteplatz 01, 10098 Berlin, Germany
CORRESP. AUTHOR EMAIL: thomas.doerner@charite.de

Current Opinion in Rheumatology (Curr. Opin. Rheumatol.) (United States) May 1, 2008, 20/3 (263-268)
CODEN: CORHE ISSN: 1040-8711
PUBLISHER ITEM IDENTIFIER: 00002281200805000000007
DOI: 10.1097/BOR.0b013e3282f5e08d
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 55

8/3/20 (Item 17 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082352668 EMBASE No: 2008183103
New therapies in SLE
Ferrera F.; Filaci G.; Rizzi M.; Singh R.P.; Indiveri F.; Hahn B.H.; La

Cava A.
Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy; Department of Internal Medicine, University of Genoa, Genoa, Italy ; Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1670, United States
AUTHOR EMAIL: alacava@mednet.ucla.edu
CORRESP. AUTHOR/AFFIL: La Cava A.: Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1670, United States
CORRESP. AUTHOR EMAIL: alacava@mednet.ucla.edu

Recent Patents on Inflammation and Allergy Drug Discovery (Recent Pat. Inflamm. Allergy Drug Discov.) (Netherlands) January 1, 2008, 2/1 (11-23)
ISSN: 1872-213X
URL: http://www.ingentaconnect.com/content/ben/iad/2008/00000002/00000001/art00002
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
CLINICAL TRIALS NUMBER: NCT00001789--ClinicalTrials.gov; NCT00089804--ClinicalTrials.gov; NCT00204022--ClinicalTrials.gov; NCT00230035--ClinicalTrials.gov; NCT00298506--ClinicalTrials.gov; NCT00308204--ClinicalTrials.gov; NCT00371319--ClinicalTrials.gov; NCT00383518--ClinicalTrials.gov; NCT00404794--ClinicalTrials.gov; NCT00423098--ClinicalTrials.gov; NCT00425438--ClinicalTrials.gov; NCT00430677--ClinicalTrials.gov; NCT00479622--ClinicalTrials.gov; NCT00539838--ClinicalTrials.gov
NUMBER OF REFERENCES: 130

8/3/21 (Item 18 from file: 73)
DIALOG(R)File 73:EMBASE

0082331250 EMBASE No: 2008137184
Anti-CD20 monoclonal antibody therapy in multiple myeloma
Kapoor P.; Greipp P.T.; Morice W.G.; Rajkumar S.V.; Witzig T.E.; Greipp P.R.
Division of Hematology, Mayo Clinic, Rochester, MN, United States
AUTHOR EMAIL: greipp.patricia@mayo.edu
CORRESP. AUTHOR/AFFIL: Greipp P. T.: Mayo Clinic, 200 First Street SW, Guggenheim 1833, Rochester, MN 55905, United States
CORRESP. AUTHOR EMAIL: greipp.patricia@mayo.edu

British Journal of Haematology (Br. J. Haematol.) (United Kingdom) April 1, 2008, 141/2 (135-148)
CODEN: BJHEA ISSN: 0007-1048 eISSN: 1365-2141
DOI: 10.1111/j.1365-2141.2008.07024.x
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 120

8/3/22 (Item 19 from file: 73)
DIALOG(R)File 73:EMBASE

0082315872 EMBASE No: 2008117923
Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia
Robak T.

Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, ul. Ciolkowskiego 2, 93-510 Lodz, Poland
AUTHOR EMAIL: robaktad@csk.umed.lodz.pl
CORRESP. AUTHOR/AFFIL: Robak T.: Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, ul. Ciolkowskiego 2, 93-510 Lodz, Poland
CORRESP. AUTHOR EMAIL: robaktad@csk.umed.lodz.pl

Current Cancer Drug Targets (Curr. Cancer Drug Targets) (Netherlands) March 1, 2008, 8/2 (156-171)
CODEN: CCDTB ISSN: 1568-0096
DOI: 10.2174/156800908783769319
URL: http://docstore.ingenta.com/cgi-bin/deliver/1/u/d/ISIS/42742452.1/ben/ccdt/2008/00000008/00000002/art00010/7AA5B3460F9F307E1204693450669F3A4EDBC94253.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 134

8/3/23 (Item 20 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0082232826 EMBASE No: 2008022823
New insights and therapeutics for immune-mediated thrombocytopenia
Metjian A.; Abrams C.S.
University of Pennsylvania, School of Medicine, 421 Curie Blvd., Philadelphia, PA 19104, United States
AUTHOR EMAIL: abrams@mail.med.upenn.edu
CORRESP. AUTHOR/AFFIL: Abrams C.S.: University of Pennsylvania, Hematology-Oncology Division, School of Medicine, 421 Curie Blvd., Philadelphia, PA 19104, United States
CORRESP. AUTHOR EMAIL: abrams@mail.med.upenn.edu

Expert Review of Cardiovascular Therapy (Exp. Rev. Cardiovasc. Ther.) (United Kingdom) January 1, 2008, 6/1 (71-84)
CODEN: ERCTA ISSN: 1477-9072 eISSN: 1744-8344
DOI: 10.1586/14779072.6.1.71
URL: http://www.future-drugs.com/doi/pdf/10.1586/14779072.6.1.71
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 146

8/3/24 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2009 Dialog. All rts. reserv.

30457567 PMID: 19308735
The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells.
Eeva Jonna; Nuutinen Ulla; Ropponen Antti; Matto Mikko; Eray Mine; Pellinen Riikka; Wahlfors Jarmo; Pelkonen Jukka
Department of Clinical Microbiology, University of Kuopio, Yliopistoranta 1C, 70210, Kuopio, Finland. eeva@hytti.uku.fi
Apoptosis - an international journal on programmed cell death (United States) May 2009, 14 (5) p687-98, ISSN 1573-675X--Electronic
Journal Code: 9712129
Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/25 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2009 Dialog. All rts. reserv.

18666138 PMID: 18497318 Record Identifier: PMC2481542
The antileukemia activity of a human anti-CD40 antagonist ***antibody*** , HCD122, on human chronic lymphocytic ***leukemia*** cells.
Luqman Mohammad; Klabunde Sha; Lin Karen; Georgakis Georgios V; Cherukuri Anu; Holash Jocelyn; Goldbeck Cheryl; Xu Xiaomei; Kadel Edward E; Lee Sang Hoon; Aukerman Sharon Lea; Jallal Bahija; Aziz Natasha; Weng Wen-Kai; Wierda William; O'Brien Susan; Younes Anas
Disease Area Oncology, Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA. mohammad.luqman@novartis.com
Blood (United States) Aug 1 2008, 112 (3) p711-20, ISSN 1528-0020--Electronic Journal Code: 7603509
Publishing Model Print-Electronic
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Other Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/26 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2009 Dialog. All rts. reserv.

18471647 PMID: 18381108
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's ***lymphoma*** .
Martin Peter; Furman Richard R; Ruan Jia; Elstrom Rebecca; Barrientos Jacqueline; Niesvizky Ruben; Coleman Morton; Leonard John P
Center for Lymphoma and Myeloma, Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA.
Seminars in hematology (United States) Apr 2008, 45 (2) p126-32, ISSN 0037-1963--Print Journal Code: 0404514
Publishing Model Print
Document type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/27 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

151356557 CA: 151(16)356557w PATENT
Purification of proteins
INVENTOR(AUTHOR): Moya, Wilson; Jaber, Jad
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20090232737 A1 DATE: 20090917
APPLICATION: US 2008316708 (20081216) *US 2006PV876330 (20061221) *US

20074319 (20071220)
PAGES: 22pp., Cont.-in-part of U.S. Ser. No. 4,319. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424009100
IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0049/00	A	I	F	B	20060101	20090917	H US
C07K-0001/30	A	I	L	B	20060101	20090917	H US
A61K-0038/12	A	I	L	B	20060101	20090917	H US
A61P-0043/00	A	I	L	B	20060101	20090917	H US
A61K-0039/395	A	I	L	B	20060101	20090917	H US

8/3/28 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

151218686 CA: 151(10)218686m PATENT
Combination of an anti-EDb fibronectin antibody-il-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
INVENTOR(AUTHOR): Neri, Dario; Menssen, Hans Dietrich; Menrad, Andreas; Schliemann, Christoph
LOCATION: Germany,
ASSIGNEE: Bayer Schering Pharma Aktiengesellschaft
PATENT: European Pat. Appl. ; EP 2085095 A1 DATE: 20090805
APPLICATION: EP 200875044 (20080117)
PAGES: 31pp. CODEN: EPXXDW LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0038/20	A	I	F	B	20060101	20080624	H EP
A61K-0039/395	A	I	L	B	20060101	20080624	H EP
A61K-0047/48	A	I	L	B	20060101	20080624	H EP
A61K-0039/44	A	I	L	B	20060101	20080624	H EP
A61P-0035/00	A	I	L	B	20060101	20080624	H EP
A61P-0037/06	A	I	L	B	20060101	20080624	H EP

DESIGNATED COUNTRIES: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; AL; BA; MK; RS

8/3/29 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

151196330 CA: 151(9)196330m PATENT
Combination of anti-EDb fibronectin antibody-IL-2 fusion protein and molecule binding to B cells, B cell progenitors and/or their cancerous counterpart for treating cancer, lymphoma and autoimmune disease
INVENTOR(AUTHOR): Neri, Dario; Menssen, Hans Dietrich; Menrad, Andreas; Schliemann, Christoph
LOCATION: Germany,
ASSIGNEE: Bayer Schering Pharma Aktiengesellschaft
PATENT: PCT International ; WO 2009089858 A1 DATE: 20090723
APPLICATION: WO 2008EP9441 (20081108) *EP 200875044 (20080117)
PAGES: 48pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0038/20	A	I	F	B	20060101		H EP
A61K-0039/395	A	I	L	B	20060101		H EP
A61K-0047/48	A	I	L	B	20060101		H EP

A61K-0039/44 A I L B 20060101 H EP
A61P-0035/00 A I L B 20060101 H EP
A61P-0037/06 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; ST; SV; SY; TJ; TM; TN; TR DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/30 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

151189980 CA: 151(9)189980v PATENT
Combination of the application of antibodies for immunostimulation together with glucocorticoids, and methods for eliminating the release of a disease-associated cytokine
INVENTOR(AUTHOR): Heiss, Markus M.; Lindhofer, Horst
LOCATION: Germany,
PATENT: U.S. Pat. Appl. Publ. ; US 20090191201 A1 DATE: 20090730
APPLICATION: US 2007977856 (20071026) *WO 2005EP4468 (20050426)
PAGES: 49pp., Cont.-in-part of Appl. No. PCT/EP2005/004468. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424136100
IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 20090730 H US
A61P-0035/00 A I L B 20060101 20090730 H US

8/3/31 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

151099675 CA: 151(5)99675v PATENT
Purification of proteins via precipitation using polyelectrolytes
INVENTOR(AUTHOR): Moya, Wilson; Jaber, Jad
LOCATION: USA
ASSIGNEE: Millipore Corporation
PATENT: PCT International ; WO 200982443 A2 DATE: 20090702
APPLICATION: WO 2008US13736 (20081216) *US 20074319 (20071220)
PAGES: 64pp., Cont.-in-part of U.S. Ser. No. 4,319. CODEN: PIXXD2
LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0001/30 A I F B 20060101 H EP
C07K-0001/32 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; ST; SV; SY; TJ; TM; TN; TR DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN;

GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ;
TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/32 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

150492918 CA: 150(23)492918w PATENT
Antibodies specific to multiple membrane spanning antigen in combination with cholesterol-modulating agent for treating cancer, inflammation, HIV-1 infection and autoimmune disease
INVENTOR(AUTHOR): Golab, Jakub; Winiarska, Magdalena; Parren, Paul; Mackus, Wendy; Engelberts, Patrick
LOCATION: Den.
ASSIGNEE: Genmab A/S; Medical University of Warsaw
PATENT: PCT International ; WO 200952830 A1 DATE: 20090430
APPLICATION: WO 2008DK50256 (20081022) *DK 20071519 (20071022)
PAGES: 113pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 H EP
C07K-0016/28 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; ST; SV; SY; TJ; TM; TN; TR DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/33 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

150281342 CA: 150(14)281342r PATENT
Activatable antibodies comprising binding, masking and cleavable moieties for prodrug development, drug screening and disease diagnosis and therapy
INVENTOR(AUTHOR): Daugherty, Patrick Sean; Stagliano, Nancy E.; Thomas, Jerry; Kamath, Kathryn; West, James W.; Khare, Sanjay
LOCATION: USA
ASSIGNEE: The Regents of the University of California; Cytomx, LLC
PATENT: PCT International ; WO 200925846 A2 DATE: 20090226
APPLICATION: WO 2008US9974 (20080821) *US 2007PV957453 (20070822) *US 2007PV957449 (20070822) *US 2008PV52986 (20080513)
PAGES: 161pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0014/00 A I F B 20060101 H KR
A61K-0039/39 A I L B 20060101 H KR
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; ST; SV; SY; TJ; TM; TN; TR DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV;

MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN;
GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ;
TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/34 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

150160095 CA: 150(9)160095d PATENT
Use of adenosine A2A receptor agonists and phosphodiesterase (PDE) inhibitors for the treatment of B-cell proliferative disorders, and combinations with other agents
INVENTOR(AUTHOR): Rickles, Richard; Lee, Margaret S.
LOCATION: USA
ASSIGNEE: CombinatoRx, Incorporated
PATENT: PCT International ; WO 200911893 A2 DATE: 20090122
APPLICATION: WO 2008US8758 (20080717) *US 2007PV950307 (20070717) *US 2007PV965587 (20070821)
PAGES: 70 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0031/7076	A	I	F	B	20060101	H	US
A61K-0038/20	A	I	L	B	20060101	H	US
A61K-0031/519	A	I	L	B	20060101	H	US
A61K-0031/4015	A	I	L	B	20060101	H	US
A61K-0031/675	A	I	L	B	20060101	H	US
A61K-0031/56	A	I	L	B	20060101	H	US
A61K-0031/573	A	I	L	B	20060101	H	US
A61K-0031/69	A	I	L	B	20060101	H	US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; ST; SV; SY; TJ; TM; TN; TR DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/35 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

150076068 CA: 150(5)76068q PATENT
Antibodies combined with radiotherapy for treating EGFR-associated tumors
INVENTOR(AUTHOR): Overgaard, Jens
LOCATION: Den.
ASSIGNEE: Genmab A/S
PATENT: PCT International ; WO 2008154927 A1 DATE: 20081224
APPLICATION: WO 2008DK50142 (20080617) *US 2007PV936623 (20070621)
PAGES: 42pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0039/395	A	I	F	B	20060101	H	EP
C07K-0016/28	A	I	L	B	20060101	H	EP
A61K-0041/00	A	I	L	B	20060101	H	EP
A61N-0005/10	A	I	L	B	20060101	H	EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR;

BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES;
FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN;
KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX;
MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG;
SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV;
MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN;
GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ;
TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/36 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

150054215 CA: 150(4)54215h PATENT
Optimized antibodies that target CD19 or other antigens with increased affinity to FCγIIb
INVENTOR(AUTHOR): Chu, Seung Yup; Desjarlais, John R.; Karki, Sher Bahadur; Lazar, Gregory Alan; Moore, Gregory; Vostiar, Igor
LOCATION: USA
ASSIGNEE: Xencor, Inc.
PATENT: PCT International ; WO 2008150494 A1 DATE: 20081211
APPLICATION: WO 2008US6915 (20080530) *US 2007PV940776 (20070530) *US 2007PV953174 (20070731) *US 2007PV970413 (20070906) *US 2007PV976279 (20070928) *US 2007PV990509 (20071127) *US 2007PV12035 (20071206) *US 2007PV13775 (20071214) *US 2008PV19395 (20080107) *US 2008PV32059 (20080227) *US 2008PV43585 (20080409) *US 2008PV46397 (20080418)
PAGES: 160pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0016/28 A I F B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/37 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

150028920 CA: 150(3)28920q PATENT
Use of labeled and unlabeled monoclonal antibodies to tumor antigens in cancer immunotherapy
INVENTOR(AUTHOR): Hasmann, Max; Lenz, Helmut; Scheuer, Werner
LOCATION: Switz.
ASSIGNEE: F.Hoffmann-La Roche AG
PATENT: PCT International ; WO 2008148546 A2 DATE: 20081211
APPLICATION: WO 2008EP4456 (20080604) *EP 200711087 (20070606)
PAGES: 49pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0016/00 A I F B 20060101 H EP
A61K-0049/00 A I L B 20060101 H EP

A61P-0035/00 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/38 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

150019100 CA: 150(2)19100v PATENT
Fab arm exchange to form bispecific IgG4 antibodies and their stabilization by amino acid substitutions in the heavy chain constant region
INVENTOR(AUTHOR): Van de Winkel, Jan; Vink, Tom; Schuurman, Janine; Parren, Paul; Aalberse, Rob; Van der Neut Kolfschoten, Marijn
LOCATION: Den.
ASSIGNEE: Genmab A/S
PATENT: PCT International ; WO 2008145142 A1 DATE: 20081204
APPLICATION: WO 2008DK50129 (20080530) *DK 2007792 (20070531) *DK 2007793 (20070531) *DK 20071002 (20070706)
PAGES: 98pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0016/28 A I F B 20060101 H EP
A61K-0047/48 A I L B 20060101 H EP
A61K-0039/395 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/39 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

150016083 CA: 150(2)16083f PATENT
CD16- and monoclonal antibody-based method for treating a malignant pathology, an autoimmune disease or an infectious disease
INVENTOR(AUTHOR): De Romeuf, Christophe; Fournier, Nathalie; Fernandez, Nadine
LOCATION: Fr.
ASSIGNEE: LFB Biotechnologies
PATENT: PCT International ; WO 2008145866 A1 DATE: 20081204
APPLICATION: WO 2008FR598 (20080425) *FR 20073013 (20070425)
PAGES: 62pp. CODEN: PIXXD2 LANGUAGE: French
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 H EP
A61K-0035/14 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/40 (Item 14 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

150016022 CA: 150(2)16022k PATENT
Detection and quantitation of calicheamicin in antibody conjugates
INVENTOR(AUTHOR): Xue, Yuzhu; Davis, Jennifer Ann; Jiang, Zhiping; Amorusi, Peter; Ji, Allena Ji
LOCATION: USA
ASSIGNEE: Wyeth, John, and Brother Ltd.
PATENT: U.S. Pat. Appl. Publ. ; US 20080299668 A1 DATE: 20081204
APPLICATION: US 2008132176 (20080603) *US 2007PV933182 (20070604)
PAGES: 15pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 436094000
IPCR/8 + Level Value Position Status Version Action Source Office:
G01N-0033/00 A I F B 20060101 20081204 H US

8/3/41 (Item 15 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149525387 CA: 149(24)525387g PATENT
Improving the immune response to neoplasms, an autoimmune disease or infection by antibody-dependent activation of CD16-bearing cells
INVENTOR(AUTHOR): De Romeuf, Christophe; Fournier, Nathalie; Fernandez, Nadine
LOCATION: Fr.
ASSIGNEE: Laboratoire Francais du Fractionnement et des Biotechnologies
PATENT: France Demande ; FR 2915398 A1 DATE: 20081031
APPLICATION: FR 20073013 (20070425)
PAGES: 71pp. CODEN: FRXXBL LANGUAGE: French
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 20081031 H FR
A61K-0035/14 A I L B 20060101 20081031 H FR
A61P-0031/00 A I L B 20060101 20081031 H FR
A61P-0033/00 A I L B 20060101 20081031 H FR
A61P-0035/00 A I L B 20060101 20081031 H FR
A61P-0037/00 A I L B 20060101 20081031 H FR

8/3/42 (Item 16 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149469365 CA: 149(21)469365j PATENT
Antagonist human anti-human CD40 monoclonal antibodies for treating cancer, carcinoma, inflammation and autoimmune disease
INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror, Isabel; Chen, Bao-Lu; Lu, Xiaofeng; Lee, Sang Hoon; Hurst, Deborah; Aukerman, Sharon Lea; Lopes de Menezes, Daniel E.
LOCATION: USA
ASSIGNEE: Novartis Vaccines and Diagnostics, Inc.
PATENT: U.S. Pat. Appl. Publ. ; US 20080254026 A1 DATE: 20081016
APPLICATION: US 2007932472 (20071031) *US 2003PV517337 (20031104) *US 2003PV525579 (20031126) *US 2004PV565709 (20040426) *US 2004PV565710 (20040427) *US 2004PV565634 (20040427) *US 2004PV611794 (20040921) *US 2004PV613885 (20040928) *WO 2004US36957 (20041104) *WO 2004US37152 (20041104) *WO 2004US37281 (20041104) *WO 2004US36954 (20041104) *WO 2004US36955 (20041104) *WO 2004US37159 (20041104) *WO 2004US36958 (20041104) *US 2006577642 (20061120) *US 2006576943 (20061201) *US 2007578400 (20070103) *US 2007578401 (20070103) *US 2007578590 (20070305) *US 2007578387 (20070327)
PAGES: 197pp., Cont.-in-part of U.S. 577,390. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424133100
IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0039/395	A	I	F	B	20060101	20081016	H	US
C07K-0016/18	A	I	L	B	20060101	20081016	H	US
C12N-0005/06	A	I	L	B	20060101	20081016	H	US
A61P-0001/00	A	I	L	B	20060101	20081016	H	US
A61P-0037/00	A	I	L	B	20060101	20081016	H	US
G01N-0033/574	A	I	L	B	20060101	20081016	H	US
C07H-0021/00	A	I	L	B	20060101	20081016	H	US

8/3/43 (Item 17 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149446286 CA: 149(20)446286v PATENT
CD80 antagonists in treatment of Hodgkin's lymphoma
INVENTOR(AUTHOR): Molina, Arturo; Hariharan, Kandasamy; Ho, Steffan
LOCATION: USA
ASSIGNEE: Biogen Idec Inc.
PATENT: PCT International ; WO 2008121821 A1 DATE: 20081009
APPLICATION: WO 2008US58660 (20080328) *US 2007PV908646 (20070328)
PAGES: 52pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:

C07K-0016/28	A	I	F	B	20060101		H	EP
A61K-0039/395	A	I	L	B	20060101		H	EP
A61P-0035/00	A	I	L	B	20060101		H	EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/44 (Item 18 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149423753 CA: 149(19)423753f PATENT
Application of labeled and non-labeled monoclonal antibodies for dosage optimization
INVENTOR(AUTHOR): Lenz, Helmut; Scheuer, Werner
LOCATION: Switz.
ASSIGNEE: F. Hoffmann-La Roche A.-G.
PATENT: PCT International ; WO 2008119493 A1 DATE: 20081009
APPLICATION: WO 2008EP2395 (20080327) *EP 20076617 (20070330)
PAGES: 50pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0016/00 A I F B 20060101 H EP
A61K-0049/00 A I L B 20060101 H EP
A61P-0035/00 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/45 (Item 19 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149244362 CA: 149(11)244362f PATENT
Multivariable antigens complexed with targeting humanized monoclonal antibody (MATCHMAB)
INVENTOR(AUTHOR): Zurawski, Gerard
LOCATION: USA
ASSIGNEE: Baylor Research Institute
PATENT: PCT International ; WO 200897817 A2 DATE: 20080814
APPLICATION: WO 2008US52714 (20080131) *US 2007PV888029 (20070202)
PAGES: 67pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0016/28 A I F B 20060101 H US
DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/46 (Item 20 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149244360 CA: 149(11)244360d PATENT
Anti-DC-ASGPR antibodies conjugated with antigen for targeting antigen-presenting cell and enhancing antigen presentation against cancer and infection
INVENTOR(AUTHOR): Banchereau, Jacques F.; Oh, Sangkon; Zurawski, Gerard; Zurawski, Sandra; Li, Dapeng
LOCATION: USA
ASSIGNEE: Baylor Research Institute
PATENT: PCT International ; WO 200897870 A2 DATE: 20080814
APPLICATION: WO 2008US52865 (20080202) *US 2007PV888036 (20070202)
PAGES: 61pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:

C12N-0005/06	A	I	F	B	20060101	H	US
A61K-0039/395	A	I	L	B	20060101	H	US
A61K-0039/00	A	I	L	B	20060101	H	US
C07K-0016/18	A	I	L	B	20060101	H	US
C12N-0009/00	A	I	L	B	20060101	H	US
A61K-0035/12	A	I	L	B	20060101	H	US
A61P-0037/00	A	I	L	B	20060101	H	US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/47 (Item 21 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149098856 CA: 149(5)98856b PATENT
Purification of proteins from a mixture by adding one or more polymers that reversibly and selectively bind to proteins
INVENTOR(AUTHOR): Moya, Wilson; Jaber, Jad
LOCATION: USA
ASSIGNEE: Millipore Corporation
PATENT: PCT International ; WO 200879280 A1 DATE: 20080703
APPLICATION: WO 2007US26040 (20071220) *US 2006PV876330 (20061221)
PAGES: 45pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:

C07K-0001/14	A	I	F	B	20060101	H	US
C07K-0001/30	A	I	L	B	20060101	H	US
C07K-0001/36	A	I	L	B	20060101	H	US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;

ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/48 (Item 22 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149098855 CA: 149(5)98855a PATENT
Purification of proteins from a mixture containing impurities by adding, mixing and precipitating one or more polymers that bind to impurities
INVENTOR(AUTHOR): Moya, Wilson
LOCATION: USA
ASSIGNEE: Millipore Corporation
PATENT: PCT International ; WO 200879302 A2 DATE: 20080703
APPLICATION: WO 2007US26090 (20071220) *US 2006PV876330 (20061221)
PAGES: 51pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
A23J-0001/00 A I F B 20060101 H US
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/49 (Item 23 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149051938 CA: 149(3)51938q PATENT
Chimeric antibodies comprising New World primate CDR for diagnosing and treating tumor, immune, inflammatory, infectious or central nervous system diseases
INVENTOR(AUTHOR): Jennings, Philip A.; Doyle, Anthony G.; Clarke, Adam W.
LOCATION: Australia
PATENT: U.S. Pat. Appl. Publ. ; US 20080139790 A1 DATE: 20080612
APPLICATION: US 2006636338 (20061208)
PAGES: 34pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 530387300
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0016/00 A I F B 20060101 20080612 H US

8/3/50 (Item 24 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

149030421 CA: 149(2)30421a PATENT
Recombinant antibodies with variant Fc regions and affinity to FcγR for treating cancer, infection, inflammation and autoimmune disease
INVENTOR(AUTHOR): Stavenhagen, Jeffrey B.; Koenig, Scott
LOCATION: USA
ASSIGNEE: Macrogenics, Inc.
PATENT: U.S. Pat. Appl. Publ. ; US 20080138349 A1 DATE: 20080612

APPLICATION: US 2007952568 (20071207) *US 2006PV869254 (20061208)
PAGES: 174pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424144100
IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0039/395	A	I	F	B	20060101	20080612	H	US
C07K-0016/28	A	I	L	B	20060101	20080612	H	US
C07K-0016/24	A	I	L	B	20060101	20080612	H	US

8/3/51 (Item 25 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

148536040 CA: 148(24)536040u PATENT
Identification and engineering of antibodies with variant Fc regions and methods of their use for disease treatment
INVENTOR(AUTHOR): Stavenhagen, Jeffrey B.; Gorlatov, Sergey; Rankin, Christopher; Tuaillon, Nadine
LOCATION: USA
ASSIGNEE: Macrogenics, Inc.
PATENT: U.S. Pat. Appl. Publ. ; US 20080112961 A1 DATE: 20080515
APPLICATION: US 2007869410 (20071009) *US 2006PV850674 (20061009)
PAGES: 164pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424155100
IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0039/395	A	I	F	B	20060101	20080515	H	US
C07H-0021/04	A	I	L	B	20060101	20080515	H	US
C12P-0021/06	A	I	L	B	20060101	20080515	H	US
C12N-0005/06	A	I	L	B	20060101	20080515	H	US
C07K-0016/30	A	I	L	B	20060101	20080515	H	US

8/3/52 (Item 26 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

148493805 CA: 148(22)493805c PATENT
Humanized anti-human CD38 antibodies and conjugates for diagnosis and treatment of cancer, asthma, autoimmune disease and inflammation
INVENTOR(AUTHOR): Park, Peter U.; Bartle, Laura M.; Skaletskaya, Anna; Golmakher, Viktor S.; Tavares, Daniel; Deckert, Jutta; Mikol, Vincent; Blanc, Veronique
LOCATION: Fr.
ASSIGNEE: Sanofi-Aventis
PATENT: PCT International ; WO 200847242 A2 DATE: 20080424
APPLICATION: WO 2007IB4172 (20071016) *EP 2006291628 (20061019)
PAGES: 133pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:

C07K-0016/00	A	I	F	B	20060101		H	EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;

ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/53 (Item 27 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

148441015 CA: 148(20)441015a PATENT
Use of sphingomyelin in combination with corticosteroids and apoptosis-inducing agents in treatment of autoimmune disease
INVENTOR(AUTHOR): Modrak, David E.; Goldenberg, David M.
LOCATION: USA
ASSIGNEE: Center for Molecular Medicine and Immunology
PATENT: U.S. Pat. Appl. Publ. ; US 20080096845 A1 DATE: 20080424
APPLICATION: US 2007857303 (20070918) *US PV126189 (19990325) *US 2000533799 (20000324) *US 2003366704 (20030214)
PAGES: 13pp., Cont.-in-part of U.S. Ser. No. 366,704. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 514119000
IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0031/66 A I F B 20060101 20080424 H US
A61P-0037/00 A I L B 20060101 20080424 H US

8/3/54 (Item 28 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

148347328 CA: 148(16)347328h PATENT
Use of high dose cyclophosphamide or other oxazaphosphorine drug in combination with anti-idiotypic vaccines in anticancer therapy
INVENTOR(AUTHOR): Brodsky, Robert; Jones, Richard J.; O'Donnell, Frank; Bonitz, Susan; Santos, Carlos
LOCATION: USA
ASSIGNEE: The Johns Hopkins University; Accentia Biopharmaceuticals, Inc.
PATENT: PCT International ; WO 200834074 A2 DATE: 20080320
APPLICATION: WO 2007US78521 (20070914) *US 2006PV844830 (20060915)
PAGES: 24pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 H US
A61K-0031/664 A I L B 20060101 H US
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/55 (Item 29 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

148347325 CA: 148(16)347325e PATENT
Use of high dose cyclophosphamide or other oxazaphosphorine drug in

combination with immune therapeutics in anticancer therapy
INVENTOR(AUTHOR): Brodsky, Robert; Jones, Richard J.; Ambinder, Richard F.
LOCATION: USA
ASSIGNEE: The Johns Hopkins University
PATENT: PCT International ; WO 200834076 A2 DATE: 20080320
APPLICATION: WO 2007US78524 (20070914) *US 2006PV844831 (20060915)
PAGES: 25pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 H US
A61K-0031/664 A I L B 20060101 H US
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/56 (Item 30 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

148306444 CA: 148(14)306444z PATENT
Multispecific human antibodies derived phage display library for cancer therapy
INVENTOR(AUTHOR): Fuh, Germaine; Bostrom, Jenny M.
LOCATION: USA
ASSIGNEE: Genentech, Inc.
PATENT: PCT International ; WO 200827236 A2 DATE: 20080306
APPLICATION: WO 2007US18385 (20070817) *US 2006PV841350 (20060830) *US 2007PV937814 (20070628)
PAGES: 149pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
C07K-0016/00 A I F B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/57 (Item 31 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

148113274 CA: 148(6)113274k PATENT
Use of an anti-neutrophil-chemoattractant agent for the prevention of rash in patients undergoing anti-epidermal growth factor receptor (anti-EGFR) therapy

INVENTOR(AUTHOR): Edvardsen, Klaus; Lisby, Steen; Baadsgaard, Ole
LOCATION: Den.
ASSIGNEE: Genmab A/S
PATENT: PCT International ; WO 200803317 A1 DATE: 20080110
APPLICATION: WO 2007DK334 (20070703) *DK 2006915 (20060703) *DK 2007727 (20070515) *DK 2007901 (20070622)
PAGES: 58pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
?